"Attach Registry Form Label Here"

AsthmaNet REGISTRY FORM

Participant's Last Name:
Participant's First Name:
Participant's Initials:
Coordinator ID:

(Coordinator Completed by Interview)

Search the AsthmaNet Registry. If the participant has incomplete status or is not found in the registry, complete the Registry form and enter/update the participant's information appropriately.

V D	RAIRA	ICTD	ATIVE	•

ADN	MINISTRATIVE	
1.	Three-digit ID for site registering participant and maintaining source documentation:	(SITE_REG)
2.	Is the participant ≥ 18 years old? → If NO , skip to Q3.	(1000) \square_1 Yes \square_0 No
	 2a. IF YES: Did the participant sign and date an AsthmaNet Protocol Informed Consent and a HIPAA Authorization Form? → If NO, STOP HERE. Data cannot be entered into the AsthmaNet Registry. 	(1010) □ ₁ Yes □ ₀ No
	2ai. IF YES: Record the date the consent form was signed.→ Skip to Q5.	(1020)//
3.	If the participant is < 18 years old, did the parent/legal guardian sign and date an AsthmaNet Protocol Informed Consent and a HIPAA Authorization Form? → If NO, STOP HERE. Data cannot be entered into the AsthmaNet Registry.	(1030) □₁ Yes □₀ No
	3a. If YES : Record the date the consent form was signed.	(1040) / /
4.	Did the participant sign and date an AsthmaNet Protocol Informed Assent and HIPAA Authorization form according to local IRB rules and regulations? → If NO, STOP HERE. Data cannot be entered into the AsthmaNet Registry. → If NOT REQUIRED, skip to Q5.	(1050) □₁ Yes □₀ No □₂ Not required by IRB
	4a. If YES : Record the date assent was given.	(1060)//
DEN	IOGRAPHICS	
5.	Participant's date of birth (Ask the participant his/her date of birth.)	(1070)//
6.	Participant's gender	(1080) □₁ Male □₂ Female

AsthmaNet REGISTRY FORM

Participant's Last Name: _	
Participant's First Name:	

7.		icipant's ethnic backgroot the participant to iden		background.)	(1090)	_	Hispanic Not Hisp		
8.	(Ask	icipant's racial backgro the participant to iden Yes.)		Check at least					
	8a.	American Indian or Al	laskan Native		(1100)		Yes	\square_0	No
	8b.	Asian			(1110)		Yes	\square_0	No
	8c.	Black or African Amer	rican		(1120)		Yes	\square_0	No
	8d.	White			(1130)		Yes	\square_0	No
	8e.	Native Hawaiian or O	ther Pacific Island	er	(1140)		Yes	\square_0	No
9.	pare	icipant's primary racial ent/guardian or participa cribes the participant, a	ant which category	/ best	(1150)	$ \begin{array}{c} \square_2\\\square_3\\\square_4\\\square_5 \end{array} $	Native Asian or	Paci Afric	ian or Alaskan fic Islander an American atino

Registry Form Storage Instructions:

Print the participant's Registry Report with his/her name on the report. Registry Reports and completed Registry forms should be stored alphabetically by participant's last name in the AsthmaNet Registry binder.

REGISTRY FORMS AND REPORTS SHOULD <u>NOT</u> BE SENT TO THE DCC.

Participant/Guardian Source Documentation
Participant/Guardian Initials: ______

Date: ____ / ___ / 20 ____

MM DD YYYY

STICS BIOME MECHANISTIC STUDY MEDICATION HISTORY

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

-								
Α	n	•	h	$\boldsymbol{\smallfrown}$	•	ı	~	2
_			LJ		и.			. •

1.		ng the past 12 months, has the participant used piotics? If YES , record the most recent date of use prior to randomization If YES , complete Q1a – Q1d	(1000)	\square_1 Yes \square_0 No \square_8 Don't Know
	1a.	How many courses of antibiotics has your child had over the past 12 months?	(1040)	courses
	1b.	Indicate most recent type of antibiotic taken prior to randomization (refer to P7_BIOME_HX_CARD reference card)	(1050)	code
		1bi. If Other , specify the name of the medication	(1050D)	
	1c.	Indicate number of milligrams per day used during the most recent use prior to randomization	(1060)	mg
	1d.	Indicate the number of days used during the most recent use prior to randomization	(1070)	days
Intr 2.		al Steroids e participant currently using nasal steroids?	(1080)	□ ₁ Yes □ ₀ No
СО	MMEN	NTS: (6000)		

STICS COORDINATOR STUDY TREATMENT QUESTIONNAIRE

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

This questionnaire is to be completed at Visit 8 by the AsthmaNet coordinator who was primarily

	ponsible for the participant's STICS visits. If a randomized he study, this form should be completed at the time of the		
Yell	ow Inhaler Contents		
1.	 Did the participant use the Yellow Zone inhaler? → If NO, stop here and complete the source documentation box below. 	(1000)	□ ₁ Yes □ ₀ No
2.	Participants in the STICS study are randomized to receive either a low-dose inhaled corticosteroid or a high-dose inhaled corticosteroid used during Yellow Zones. Please check the box next to the treatment that you believe the participant received during the study.	(1010)	\square_1 fluticasone 44 mcg/puff \square_2 fluticasone 220 mcg/puff
3.	How sure are you about your answer in Question 2?	(1020)	 □₁ Absolutely sure – I know what the Inhaler contains □₂ Moderately sure □₃ Somewhat sure □₄ Not sure at all – purely guess
4.	Please comment with respect to any observations you made Question 2. (1030D)	that help	oed you make your choice in
	Coo	rdinator	Source Documentation 's Initials: (1040) / / 20 (1050)



STICS ELIGIBILITY CHECKLIST 1

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

Informed Consent/Assent □₁ Yes ■ No Has the parent/legal guardian appropriately signed and (1000) dated the STICS Informed Consent? ____/ ____/ 20____ 1a. If **YES**, record the date the consent form was signed. (1010)Consent should be reviewed and signed on the day Visit 1 is performed. 2. Has the participant provided informed assent? **山**₁ Yes (1020)Check N/A if the participant is less than the local age **□**₀ No of assent. ____/ ____/ 20____ 2a. If **YES**, record the date the assent was given. (1030)Assent should be reviewed and signed or verbally given on the day Visit 1 is performed. **Study Medicines** ■ Yes 3. Does the participant have an intolerance or allergy to (1040) fluticasone? **]**₀ No Don't know Does the participant have an intolerance or allergy to oral 4. **J**₁ Yes (1050) corticosteroids (e.g. Decadron, Dexamethasone, Orapred, **J**₀ No Prelone, Pediapred or prednisone)? ■ Don't know □₀ No Is the participant able to take albuterol (e.g. Proventil and **□**₁ Yes 5. (1060)Ventolin)? **Medical History Criteria** 6. Is the participant 5 to 11 years old? **□**₁ Yes ■ No (1070) 7. Was the participant born before 35 weeks gestation? ■ Yes □₀ No (1080)Does the parent report that the participant is up-to-date **□**₁ Yes ■ No 8. (1090)with immunizations? 9. Has the participant ever had chicken pox or received one **□**₁ Yes □₀ No (1100)dose of the chicken pox vaccine? (Refer to MOP for discussion on immunization records) □₁ Yes □₀ No 10. Is the participant receiving allergy shots? (1110) 10a. If **YES**, has the dose been changed in the past 3 ■ Yes □ No



months?

(1120)

ELIGIBILITY CHECKLIST 1

Part. ID:	-	 	 -	 	
Visit:					

11.	Has the participant used any medications known to significantly interact with corticosteroid disposition in the past 2 weeks (including but not limited to carbamazepine, erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole)?	(1130)	□ ₁ Yes	□ ₀ No
12.	Does the participant have a chronic or active lung disease other than asthma (cystic fibrosis, BPD, etc.)?	(1140)	■₁ Yes	□₀ No
13.	Does the participant have a significant medical illness other than asthma or concurrent medical problem that could require oral or injectable corticosteroids during the study (including by not limited to thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, and hepatic disease)?	(1150)	■ ₁ Yes	□₀ No
14.	Does the participant have a history of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids?	(1160)	■ ₁ Yes	□ ₀ No
15.	Does the participant have significant developmental delay/failure to thrive (defined as below the 2 nd percentile)?	(1170)	■₁ Yes	□₀ No
16.	Does the participant have a significant medical illness other than asthma (refer to P7_EXCLMED)?	(1180)	■₁ Yes	□₀ No
Med	ication History			
17.	During the past 12 months, how many oral/systemic corticosteroid courses has the participant had?	(1190)	course	es
	17a. Is Q17 ≥ 1?	(1200)	☐₁ Yes	□ ₀ No
	17b. Is Q17 ≥ 6?	(1210)	■₁ Yes	□ ₀ No
18.	Has the participant used an oral/systemic corticosteroid for any reason in the past 2 weeks?	(1220)	■₁ Yes	□₀ No
19.	Is the participant currently taking any medications listed on the Exclusionary Drugs for STICS (P7_EXCLDRUG) reference card?	(1225)	□ ₁ Yes	□₀ No
	19a. If Yes , list:	(1225D)		
Othe	er Criteria			
20.	If this participant was re-enrolled due to an asthma exacerbation during the Run-In, has it been at least 4 weeks since the exacerbation was resolved?	(1230)	☐₁ Yes ☐₀ No ☐₀ N/A	



ELIGIBILITY CHECKLIST 1

Part. ID:	 	 	 	
√isit:				

21.	During the past 12 months, how many times has the participant been hospitalized for asthma (hospitalization lasting > 24 hours)?	(1240)		times	
	21a. Is Q21 ≥ 2?	(1250)		Yes	\square_{0} No
22.	Has the participant ever had a near-fatal asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure?	(1260)		Yes	□₀ No
23.	Currently, or within the past month, has the participant been involved in another therapeutic drug trial?	(1270)		Yes	□₀ No
24.	Does the participant's family have plans to move out of the area before the end of the study?	(1280)		Yes	□₀ No
25.	Is there any other reason for which this participant should not be included in this study?	(1290)		Yes	□₀ No
	If YES , describe	(1290D)			
26.	Is the participant eligible?	(1300)		Yes	□ ₀ No
26.	Is the participant eligible? If any of the shaded boxes is selected, the participant is in → If NO, STOP HERE.	` ,	•	Yes	□₀ No

Medication			Taking?	If YES , number of puffs/nebs/ inhalations per day	Low Dose (Step 2 Controller Therapy)	Medium Dose (Step 3 Controller Therapy)
Advair (fluticasone- salmeterol)	DPI: 100/50 mcg/inh DPI: 250/50 mcg/inh DPI: 500/50 mcg/inh	(1320 - 1330)	☐ ₁ Yes	inhs/day	None	1-2 inh 1 inh None
Advair (fluticasone- salmeterol)	HFA: 45/21 mcg/inh HFA: 115/21 mcg/inh HFA: 230/21 mcg/inh	(1340 - 1350)	☐ ₁ Yes	inhs/day	None	1-4 inh 1-2 inh 1 inh



ELIGIBILITY CHECKLIST 1

Part. ID:	 	 	
Visit:			

Medication			Taking?	If YES , number of puffs/nebs/ inhalations per day	Low Dose (Step 2 Controller Therapy)	Medium Dose (Step 3 Controller Therapy)
Symbicort (budesonide- fomoterol)	80/4.5 mcg/inh 160/4.5 mcg/inh	(1360 - 1370)	☐ ₁ Yes	inhs/day	None	1-4 inh 1-2 inh
Dulera (mometasone- formoterol)	100/5 mcg/inh 200/5 mcg/inh	(1380 - 1390)	☐ ₁ Yes	inhs/day	None	1-2 inh 1 inh
Beclomethasone	HFA: 40 mcg/puff	(1400 - 1410)	☐ ₁ Yes	puffs/day	1-4 puffs	5-8 puffs
Beclomethasone	HFA: 80 mcg/puff	(1420 - 1430)	☐ ₁ Yes	puffs/day	1-2 puffs	3-4 puffs
Budesonide	Nebulizer 0.25mg suspension	(1440 - 1450)	☐ ₁ Yes	nebs/day	1-2 nebs	3-4 nebs
Budesonide	Nebulizer 0.5mg suspension	(1460 - 1470)	☐₁ Yes	_ nebs/day	1 neb	2 nebs
Budesonide	Nebulizer 1mg suspension	(1480 - 1490)	☐ ₁ Yes	nebs/day	None	1 neb
Budesonide	Flexhaler: 90 mcg/inh	(1500 - 1510)	☐₁ Yes	inhs/day	1-4 inh	5-8 inh
Budesonide	Flexhaler: 180 mcg/inh	(1520 - 1530)	☐ ₁ Yes	inhs/day	1-2 inh	3-4 inh
Ciclesonide	HFA: 80 mcg/puff	(1540 - 1550)	☐₁ Yes	puffs/day	1-2 puffs	3-4 puffs
Ciclesonide	HFA: 160 mcg/puff	(1560 - 1570)	☐₁ Yes	puffs/day	1 puff	2 puffs
Flunisolide	HFA: 80 mcg/puff	(1580 - 1590)	☐₁ Yes	puffs/day	1-3 puffs	4-6 puffs
Fluticasone	HFA: 44 mcg/puff	(1600 - 1610)	☐ ₁ Yes	puffs/day	1-4 puffs	5-8 puffs
Fluticasone	HFA: 110 mcg/puff	(1620 - 1630)	☐ ₁ Yes	puffs/day	1 puff	2-3 puffs



ELIGIBILITY CHECKLIST 1

Part. ID:	 	 	
Visit:			

Medication			Taking?	If YES , number of puffs/nebs/ inhalations per day	Low Dose (Step 2 Controller Therapy)	Medium Dose (Step 3 Controller Therapy)
Fluticasone	HFA: 220 mcg/puff	(1640 - 1650)	☐ ₁ Yes	puffs/day	None	1 puff
Fluticasone	DPI: 50 mcg/inh	(1660 - 1670)	☐ ₁ Yes	inhs/day	1-4 inh	5-8 inh
Fluticasone	DPI: 100 mcg/inh	(1680 - 1690)	☐ ₁ Yes	inhs/day	1-2 inh	3-4 inh
Fluticasone	DPI: 250 mcg/inh	(1700 - 1710)	☐ ₁ Yes	inhs/day	None	1 inh
Mometasone	DPI: 110 mcg/inh	(1720 - 1730)	☐ ₁ Yes	inhs/day	1 inh	2-4 inh
Mometasone	DPI: 220 mcg/inh	(1740 - 1750)	☐ ₁ Yes	inhs/day	None	1-2 inh
Singulair	4 or 5 mg/tablet	(1760 - 1770)	☐ ₁ Yes	tablets/ day	1-2 tablets	1 tablet + Step 2 ICS therapy
Singulair	4 mg/packet	(1780 - 1790)	☐ ₁ Yes	packet/ day	1-2 packets	1 packet + Step 2 ICS therapy
Triamcinolone	MDI: 75 mcg/puff	(1800 - 1810)	☐ ₁ Yes	puffs/day	1-8 puffs	9-12 puffs
_	ne doses greater than the STOP HERE. The partic CS.			(1820)	Yes □₀	No
→ If Ste	participant's current dose p 2 Controller Therapy, p 3 Controller Therapy,	Skip to C			Step 2 Contr Step 3 Contr	
•	s taking low-dose ICS + L d Step 3 Controller Thera		uld be			
Naïve to Control	ler Therapy					
week did the	over the past 4 weeks, he participant have asthma cluding pre-medication p	sympton	ns or use	(1840)	days	
30a. Is Q30	> 2?			(1850)	Yes \square_0	No

ELIGIBILITY CHECKLIST 1

Part. ID:	 	 	-	 	
Visit:					

31.	How many nights in the past 4 weeks did the participant have nighttime awakenings due to asthma?	(1860)	nights	
	31a. ls Q31 > 2?	(1870)	\square_1 Yes	$\square_{\!\scriptscriptstyle 0}$ No
32.	Is the response to Q30a or Q31a YES ? → Skip to Q36.	(1880)	☐ ₁ Yes	□₀ No
Step	3 Controller Therapy			
Clin	ic Use Only			
33.	What is the participant's Visit 1 C-ACT score?		score	
	33a. Is Q33 > 19?	(1890)	□₁ Yes	□ ₀ No
34.	How many asthma exacerbations requiring oral or systemic corticosteroids has the participant had in past 6 months?	(1900)	exace	rbations
	34a. Is Q34 <= 2?	(1910)	☐₁ Yes	□ ₀ No
Clin	ic Use Only			
35.	What is the participant's Visit 1 pre-bronchodilator FEV ₁ % predicted?		%	
	35a. ls Q35 >= 80%?	(1920)	☐₁ Yes	□ ₀ No
	→ If YES, the participant is eligible but current controller therapy must be stepped down. See MOP for further details.			
36.	Is the participant eligible?	(1930)	☐₁ Yes	□ ₀ No
	If any of the shaded boxes is selected, the participant is i	neligibl	e.	
	→ If NO, STOP HERE.			
CON	MMENTS: (6000)			

STICS ELIGIBILITY CHECKLIST 2

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed) **Pregnancy J**₁ Yes (1000)1. Is the participant potentially able to bear children? ₀ No (If the participant is Male, check N/A and go to Q2.) N/A 1a. If **YES**, is the participant currently pregnant or lactating? □₀ No **⊔**₁ Yes (1010)1b. If YES, does the participant agree to use one of the **□**₁ Yes ■ No (1020) approved methods indicated on the Birth Control Methods reference card (BIRTH CTRL) for the duration of the study? Spirometry 2. Is the participant able to perform reproducible spirometry **□**₁ Yes ■ No (1030)according to ATS criteria? 3. Is the participant's pre-bronchodilator $FEV_1 \ge 60\%$ of **□**₁ Yes \square_0 No (1040)predicted? Spirotel®/MDI Technique 4. Is the parent able to use the spirotel® e-diary correctly as **□**₁ Yes \square_0 No (1050)evidenced by achieving a score of 9 on the STICS spirotel® Performance Checklist (P7 SPIROTEL PERF)? 5. Is the participant able to use a metered dose inhaler **□**₁ Yes \square_0 No (1060)properly, as evidenced by achieving a score of 12 on the MDI Inhalation Technique Checklist With Spacer (TECH MDI SP)? 6. Is there any other reason for which this participant should **□**₁ Yes \bigsqcup_0 No (1070)not be included in this study? (1070D) If YES. describe 7. Is the participant eligible? **山**₁ Yes **□**₀ No (1080) If any of the shaded boxes is selected, the participant is ineligible. If NO, STOP HERE.

COMMENTS: (6000)

STICS ELIGIBILITY CHECKLIST 3

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coc	ordinator Completed)						
1.	Since Visit 1, did the participant have any exacerb requiring systemic corticosteroids? → If YES, the participant is ineligible.	oations (1	1000)		Yes	□ ₀ No	
	 1a. If YES, was the participant hospitalized? → If YES, complete the SERIOUS form. → Skip to Q8. 	(1	1010)	□ 1	Yes	□ ₀ No	
2.	Since Visit 1, did the participant take any medicati asthma other than study medications?	on for (1	1020)		Yes	□₀ No	
3.	Did the participant complete at least 75% of schedulers sessions?	duled PM (1	1030)		Yes	□ ₀ No	
	 → Use Q1c from the spirotel[®] Participant Compliant (P7_COMPLY) to answer this question. 	ance Report					
4.	Did the participant take at least 75% of the require from his or her green inhaler? → Use Q2d from the spirotel® Participant Complia (P7_COMPLY) to answer this question.	•	1040)	□ ₁	Yes	□ ₀ No	
Clini	ic Use Only						
5.	C-ACT score at visit 2		-		_ score		
	5a. Is the Visit 2 C-ACT score <20?	(1	1050)		Yes	\square_0 No	
6.	Is the participant's pre-bronchodilator $FEV_1 \ge 80\%$ predicted at Visit 2?	o of (1	1060)	□₁	Yes	□ ₀ No	
7.	Is there any other reason for which this participant not be included in this study?	t should (1	1070)		Yes	□ ₀ No	
	7a. If YES , describe:	(1	1070D)				
			-				
8.	Is the participant eligible?	(1	1080)		Yes	□ ₀ No	
	If any of the shaded boxes is selected, the part → If NO, STOP HERE.	ticipant is ine	eligible	•			
CON	MMENTS: (6000)						



STICS LABORATORY RESULTS

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

If unable to collect blood at Visit 2, samples can be collected at a later visit. Only collect samples once.

onc	e. ·		•	•
BLC	OOD TESTS and SPECIMEN COLLECTIONS (VISIT 2 – 8)			
1.	Were you able to collect a blood sample from the participant today? → If NO and Visit 2, skip to Q6.	(1000)	☐ ₁ Yes	□ ₀ No
Loc	al Laboratory Results			
2.	Total WBC	(1010)		/cu.mm
3.	Eosinophils	(1020)	%	
Exte	ernal Laboratory Samples			
4.	Were you able to collect a sample for allergen-specific IgE and total IgE?	(1030)	☐ ₁ Yes	□ ₀ No
5.	Were you able to collect a sample for genetic analysis?	(1040)	☐ ₁ Yes	\square_0 No
	→ If Visit 3-8, STOP HERE.			
NAS	SAL SAMPLING (VISIT 2 ONLY)			
6.	Were you able to collect a nasal sample from the participant today?	(1050)	☐₁ Yes	□₀ No
CON	MMENTS: (6000)			

STICS MICROBIAL EXPOSURE QUESTIONNAIRE

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed by Interview)

To the Parent/Guardian: The purpose of this questionnaire is to collect information on exposures that may affect the microbiome, or microscopic environment, of your child's lungs. When answering these questions, "you" is referring to your child who is the study participant.

GENERAL HOUSE CHARACTERISTICS

('House' is meant to refer to the place where you live most of the time.)

1.	Wha	t type of dwelling do you live in?	(1000)		Detach	ed house	
				\square_2		ed house (e.	g., row
				_		ownhouse)	at mal
						=	ondo (1 st -2 nd floor)
				\bigsqcup_4	Higher	apartment/c	ondo (3 rd + floors)
				\square_5	Mobile	home/trailer	
				\square_6		specify) (e.g	., dorm room,
					hotel)		
			(1000D)				
2.	Do y	ou live within a mile of a:					
	2a.	Port	(1010)		Yes	\square_0 No	□ ₉ N/A
	2b.	Farm	(1020)		Yes	\square_0 No	
	2c.	Power plant	(1030)		Yes	\square_0 No	
	2d.	Major highway	(1040)	\square_1	Yes	\square_0 No	
	2e.	Other source of airborne particulate matter (e.g., factory, airport, industrial plant, etc.)	(1050)		Yes	□ ₀ No	
		2ei. If YES , please specify source	(1050D)				

MICROBIAL EXPOSURE QUESTIONNAIRE

Part. ID:	-	 	 -	 	
Visit:					

3.	What is the main heating source in your house?	(1060)	(1060) □₁ Radiators (steam or hot water) □₂ Forced air or central heating (vents) □₃ Electric baseboard heating □₄ Kerosene space heater □₅ Open stove or oven □₆ Natural gas fireplace □٫ Other (specify)					
		(1060D)	——————————————————————————————————————					
4.	In the past 3 months, did you use a wood burning fireplace or a wood burning stove in your house?	(1070)	\square_1 Yes \square_0 No \square	1 ₈ Don't Know				
	4a. If YES, on average, how many days per month did you use the wood burning fireplace or wood burning stove in your house during the past 3 months?	(1080)	days per month					
5.	Do you have a gas stove, gas range, gas oven, or gas fireplace in your house?	(1090)	\square_1 Yes \square_0 No \square	1 ₈ Don't Know				
6.	Of the area around your home, about 100 yards in each direction, what proportion is "natural" (e.g., grass, dirt, shrubs and trees, garden, etc.)?	(1100)						
7.	On average, how much time per week do you spend in a yard?	d (1130)	hours per week					
8.	Does the home you live in have a yard?	(1110)	□₁ Yes □₀ No					
	8a. If YES , what proportion of the yard is "natural" (e.g., grass, dirt, shrubs and trees, garden, etc.)?	(1120)						
9.	Do you garden at home?	(1140)	□₁ Yes □₀ No					
	→ If <i>NO</i> , skip to Q10.							
	9a. On average, how many hours per week do you spend gardening in the?							
	9ai. Spring	(1150)	hours per week					
	9aii. Summer	(1160)	hours per week					

MICROBIAL EXPOSURE QUESTIONNAIRE

Part. ID:	 	 ·	 	
/isit:				

		9aiii.	Fall	(1170)	hours	per week
		9aiv.	Winter	(1180)	hours	per week
	9b.		erage, how many hours per week have irdened in the past month?	(1190)	hours	per week
СНІ	LDRE	:N				
('Ch	ildren	' define	d as less than 18 years old.)			
10.	avera	•	ast 3 months, have children spent an nore than 2 hours a day in your	(1200)	□ ₁ Yes	□ ₀ No
	→ If	f NO , sl	kip to Q11.			
	10a.	How m	nany children spend time in your hold?	(1210)	childre	en
	10b.		nany children spend time in your hold that are not "potty-trained"?	(1220)	childre	en
ANI	MAL I	EXPOS	SURE			
11.	Do yo	ou curre	ently live on a farm?	(1230)	□₁ Yes	□₀ No
12.	Do yo	ou work	on a farm?	(1240)	□₁ Yes	$\square_{\scriptscriptstyle 0}$ No
	→ If <i>I</i>	NO , ski	p to Q13.			
	12a.		erage, how many months per year do ork on a farm?	(1250)	month	s per year
	12b.		erage, how many hours per week do ork on a farm during those months?	(1260)	hours	per week
	12c.		erage, how many hours per week have orked on a farm in the past month?	(1270)	hours	per week
13.	Do yo week		a farm frequently (at least 2 days per	(1280)	□ ₁ Yes	□ ₀ No
14.) with fa	e frequent contact (at least 2 days per arm animals (e.g., hoofed livestock or	(1290)	□₁ Yes	□₀ No

MICROBIAL EXPOSURE QUESTIONNAIRE

Part. ID:	-	 	 -	 	
√isit:					

15. Have you been around animals outside your home at least 2 days per week in the past 3 months?				(1300)	☐ ₁ Yes	□ ₀ No
	15a.	If YES,	have you been around animals at a?			
		15ai.	Zoo	(1310)	□₁ Yes	□ ₀ No
		15aii.	Farm	(1320)	□ ₁ Yes	□ ₀ No
		15aiii.	Park	(1330)	□ ₁ Yes	□ ₀ No
		15aiv.	Other location outside your home	(1340)	□ ₁ Yes	□ ₀ No
				(1340D)		
TOE	BACC	О ЕХРО	SURE			
16.	week) to toba restaura	ently exposed (2 or more days per cco smoke outside of your home, such nts, other homes, workplace, or other	(1350)	□ ₁ Yes	□ ₀ No
				Parti	cipant/Guardi	an Source Documentation
				Parti	cipant/Guardi	an Initials: (1360)
				Date	:/ MM DD	
Coc	ordina	tor Com	pleted			
	MMEN	ITS				

STICS PARTICIPANT STUDY TREATMENT QUESTIONNAIRE

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Parent/Legal Guardian Completed)

This questionnaire is to be completed by the parent/guardian at Visit 8. If a randomized participant terminates prior to the end of the study, please ask the parent/guardian to complete this form during the termination visit.

1.	Who is the respondent?	(1000)	-	Parent/Guardian Other (specify)
		(1000D)		
2.	Did your child use the Yellow Zone inhaler?→ If NO, stop here and complete the source documentation box below.	(1010)		Yes □₀ No
Yell	ow Inhaler Contents			
3.	As a STICS study participant, your child was randomized to receive either a low-dose inhaled corticosteroid or a high-dose inhaled corticosteroid used during Yellow Zones. Please check the box next to the treatment that you believe you received during the study .	(1020)		fluticasone 44 mcg/puff fluticasone 220 mcg/puff
4.	How sure are you about your answer to Question 3?	(1030)		Absolutely sure – I know what the Inhaler contains Moderately sure Somewhat sure Not sure at all – purely a guess
5.	Please comment with respect to any observations you made that helped you make your choice in Question 3 (for example: taste , smell , or physical sensations related to your Yellow Inhaler).	(1040)	-	I have no comments I noticed the following: (Describe below)
(104	OD)			
		•		dian Source Documentation

(1060)

____/ ____/ 20____

PHONE SYMPTOM ASSESSMENT

(Parent/Guardian Interview Completed)

	ontact ttempt	Coordinator ID	Date		Time	Contact Occurred?
	1		/	:	AM □ PM □	.
	2		/	:	AM □	
	3		/	:	AM □ PM □	
	4		//	:	AM □ PM □	
1.	to a doo	ne last visit or phone ctor for breathing pro YES , how many time		(1000) (1010)	□ ₁ Yestimes	□ ₀ No
2.	to an El		contact, has your child been for breathing problems?	(1020) (1030)	☐ ₁ Yes times	□ ₀ No
3.	hospital → If	lized for breathing pro YES, assess whether	contact, has your child been oblems? r the participant is a treatment e SERIOUS form, if needed.	(1040)	☐ ₁ Yes	□ ₀ No
4.	During to	-	d your child have wheezing or	(1050)	□ ₁ Yes	□ ₀ No
	4a. If	YES , how many days	s?	(1060)	days	
5.	due to a	the past 2 weeks, dic asthma symptoms re NO , skip to Q6.		O (1070)	☐ ₁ Yes	□ ₀ No
	5a. If	YES , how many nigh	ts?	(1080)	nights	
	5b. If	YES , was the Yellow	Zone started?	(1090)	☐ ₁ Yes	□ ₀ No
	5c. If	YES , is Q5a > 1?		(1100)	☐ ₁ Yes	□ ₀ No
	5c	i. If YES , was there	at least 2 consecutive nights?	(1110)	□ ₁ Yes	\square_0 No

PHONE SYMPTOM ASSESSMENT

Part. ID:	-	 	 -	 	
√isit:					

	5cii. Was prednisone started?→ If YES, complete the Prednisone Medication (P7_PRED) form.	(1120)	□ ₁ Yes	□ ₀ No
6.	During the past 2 weeks, did your child take any albuterol (excluding pre-exercise)?	(1130)	□₁ Yes	□₀ No
	6a. If YES , how many days?	(1140)	days	
7.	Have you been completing the spirotel [®] Diary daily? → If NO , please review adherence with parent.	(1150)	□ ₁ Yes	□ ₀ No
8.	Has your child been using the GREEN inhaler every morning and evening (except when using the YELLOW inhaler)?	(1160)	□ ₁ Yes	□ ₀ No
	8a. If YES , how many puffs are taken in the AM?	(1170)	puffs	
	8b. If YES , how many puffs are taken in the PM?	(1180)	puffs	
	→ Please review adherence with parent, if necessary.			
9.	Has your child had any Yellow Zones (during which your child used the YELLOW inhaler)?	(1190)	□ ₁ Yes	□ ₀ No
	9a. If YES , how many Yellow Zones did your child have? → Check for treatment failure.	(1200)	zones	
10.	Since the last visit or phone contact, has your child used prednisone? → If YES, complete the Prednisone Medication (P7_PRED) form.	(1210)	☐ ₁ Yes	□ ₀ No
	10a. If YES, how many courses (1 course = 4 days) of prednisone were used?→ Check for treatment failure.	(1220)	courses	
COI	MMENTS: (6000)			

STICS PREDNISONE MEDICATION

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

Complete this form each time a STICS participant receives oral/systemic corticosteroids for treatment of asthma.

Prednisone Checklist

- Administer prednisone at 2 mg/kg per day for 2 days (maximum 60 mg) followed by 1 mg/kg per day for 2 days (maximum 30 mg).
 - 1a. Start date of prednisone

- → Record prednisone course on the CMED form
- Why was the prednisone course prescribed?
 The STICS protocol specifications are to prescribe oral steroids if:
- - 2 12 or more puffs of albuterol in past 24 hours for asthma
 - □₃ Nighttime awakenings requiring albuterol due to cough, shortness of breath, chest tightness, or wheezing on 2 of the last 3 nights
 - 8 or more puffs of albuterol per day on 2 of the last 3 days for asthma
 - □₅ Physician discretion (If Physician discretion, please explain in the comments section below)
 - \square_6 Other (specify)

(1010D) _____

- Is this the second prednisone course for treatment of asthma within 6 months since randomization?
- → If YES, the participant is a treatment failure. Complete the P7_TRTFAIL form.

(1020) \square_1 Yes \square_0 No

3.

STICS PREDNISONE MEDICATION

Part. ID:	
Visit:	

4.	Is this the third prednisone course for treatment of asthma
	within 12 months since randomization?

(1030) \square_1 Yes \square_0 No

- → If YES, the participant is a treatment failure. Complete the P7_TRTFAIL form.
- 5. Instruct the parents to call if the child's condition worsens.
- 6. A Red Zone phone call should be made to the parents 5 days (+-2 day window) after initiation of prednisone to reassess the participant's symptoms. Complete the Red Zone Phone Assessment Form (P7_RED_PC)

COM	MENTS: (6000)	S: (6000)						

STICS PULMONARY PROCEDURE CHECKLIST

. ID:
. Initials:
:
Date: / / 20
nnician ID:

(Parent/Guardian Interview Completed)

Complete this form at all visits where baseline spirometry is required. If any medications other than study or rescue albuterol were used, record the medication(s) on the Concomitant Medications for Asthma/Allergy and Adverse Events (CMED) form.

1.	Have you consumed caffeine in the past 4 hours? Examples: Pepsi, Coke, Coffee, Mountain Dew, Tea, Rootbeer, Red Bull, 5-hour ENERGY	(1000)	■ ₁ Yes	□ ₀ No
2.	Have you used medications with caffeine in the past 4 hours? Examples: Anacin, Darvon compound, Esgic, Excedrin, Fiorinal, Fioricet, No Doz, Norgesic, Vivarin	(1010)	□ ₁ Yes	□ ₀ No
3.	Have you used any weight loss medications in the past 4 hours? Examples: Belviq, bitter orange, Xenadrine, EFX, Thermorexin, Qsymia	(1020)	□₁ Yes	□ ₀ No
4.	Have you consumed any food containing alcohol or beverages containing alcohol in the past 4 hours?	(1030)	■₁ Yes	\square_0 No
5.	Have you used a rescue intermediate-acting inhaled beta-agonist in the past 6 hours? Examples: albuterol (Proventil), study RESCUE (ProAir®)	(1040)	□ ₁ Yes	□ ₀ No
6.	(Visit 1 only) Have you used a short-acting anticholinergic in the past 6 hours? Examples: ipratropium (Atrovent, Combivent)	(1050)	■ ₁ Yes	□ ₀ No
7.	Have you used any ophthalmic antihistamines in the past 6 hours? Examples: Alaway, Elestat, Emadine, Optivar, Pataday, Patanol, Zaditor	(1060)	☐ ₁ Yes	□₀ No
8.	Have you used any nasal antihistamines in the past 6 hours? Examples: Astelin, Astepro, Livostin, Patanase	(1070)	☐ ₁ Yes	□ ₀ No
9.	Have you used any nasal decongestants in the past 6 hours? Examples: oxymetazoline (Afrin)	(1080)	☐ ₁ Yes	□ ₀ No
10.	Have you used any oral antihistamines in the past 48 hours? Examples: Allegra, Benadryl, Chlor-Trimeton, Clarinex, Claritin, Tylenol PM	(1090)	□₁ Yes	□ ₀ No

PULMONARY PROCEDURE CHECKLIST

Part. ID:	
Visit:	

COI	MMENTS: (6000)				-
	If any of the shaded boxes is selected, the participant is oxide and IOS testing.	ineligibl	e for spiro	metry, exhaled n	itric
15.	Is the participant eligible to proceed with the spirometry testing?	(1140)	☐₁ Yes	□₀ No	
	If YES, explain:	(1130D)			_
14.	Is there any other reason you should not proceed with spirometry testing?	(1130)	■ ₁ Yes	$\square_{\scriptscriptstyle 0}$ No	
13.	At this time, is your asthma worse because of recent exposure to triggers? Examples: cold air, smoke, allergens, recent exercise, a recent respiratory tract infection, or other pulmonary infection	(1120)	☐ ₁ Yes	□₀ No	
12.	Have you used any smokeless tobacco products today? Examples: chewing tobacco, snuff	(1110)	☐ ₁ Yes	□₀ No	
11.	Have you used any oral decongestants or cold remedies in the past 48 hours? Examples: pseudoephedrine (Sudafed), Tylenol Allergy	(1100)	□₁ Yes	□ _o No	

RED ZONE PHONE ASSESSMENT

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

		Guardian Interview Completed)			
		ordinator Completed) Record related Concomitant dication Number	(1000)		
	ls th →	ne participant still having asthma symptoms? If NO , Skip to Q3.	(1010)	□₁ Yes	□ ₀ No
	2a.	Has the participant used more than 3 nebulizer treatments with albuterol or 6 puffs of albuterol (3 treatments of 2 puffs each) in 4 hours for relief of asthma symptoms?	(1020)	□ ₁ Yes	□ ₀ No
	2b.	Has the participant used 12 or more puffs of albuterol in 24 hours for relief of asthma symptoms?	(1030)	☐ ₁ Yes	\square_0 No
	2c.	Has the participant had nighttime awakenings on 2 out of 3 consecutive nights due to cough, shortness of breath, chest tightness, or wheezing and used albuterol?	(1040)	□ ₁ Yes	□ ₀ No
	2d.	Has the participant used 8 or more puffs of albuterol per day on 2 out of 3 consecutive days for relief of asthma symptoms?	(1050)	☐ ₁ Yes	□ ₀ No
		→ If 2a, 2b, 2c, or 2d is 'Yes', the study physician show Additional treatment, a follow-up phone call or a visit			
	Hav →	re you been completing the spirotel [®] Diary daily? If NO , please review adherence with the parent.	(1060)	☐ ₁ Yes	\square_0 No
٦N	име	NTS: (6000)			

STICS TERMINATION OF STUDY PARTICIPATION

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

ordinator Completed)			
plete this form only for participants who successfully	completed	Visit 1.	
Is the participant a Run-In failure? → If No, skip to Q2	(1000)	□₁Yes	□ ₀ No
1a. Indicate the primary reason the participant was a Ri	un-In failure.		
□₁ inability to demonstrate adherence with spirotel® □₂ inability to demonstrate adherence with study m □₃ too few asthma symptoms during Run-In □₄ too many asthma symptoms during Run-In □₃ asthma exacerbation during Run-In □₃ participant required an asthma medication other □ႇ parent withdrew consent □₃ participant lost to follow up □₃ participant experienced a serious adverse event □₁₀ physician initiated termination of study participat □₁₁ other** ease complete the Serious Adverse Event Reporting ERIOUS) form. Iditional explanation required: (1010D)	r than study	medications	s since Visit 1
→ Skip to SIGNATURES section.			
Has the participant completed the study through Visit 8? → If YES, skip to SIGNATURES section.	(1020)	□ ₁ Yes	\square_0 No
Who initiated termination of the participant?	(1030)	□₁ Paren	t/Guardian
→ If participant withdrew due to impending clinical staff termination, indicate termination by clinical staff.	. ,	Q Clinica	al Staff
→ If Clinical Staff, skip to Q5.			

TERMINATION OF STUDY PARTICIPATION

Part. ID:	——	 	 	
Visit:				

4.	Indicate the primary reason the participant has withdrawn from the study.
	□₁ no longer interested in participating* (1040)
	□₂ no longer willing to follow protocol*
	□₃ difficult access to clinic (location, transportation, parking)
	unable to make visits during clinic hours
	□ ₅ moving out of the area
	unable to continue due to personal constraints*
	unable to continue due to medical condition unrelated to asthma*
	☐ ₈ side effects of study medications*
	☐ ₉ dissatisfied with asthma control
	□ ₁₀ other*
*Ad	ditional explanation required: (1040D)
	→ Skip to SIGNATURES section.
5.	Indicate the primary reason the participant was terminated by clinical staff.
	\square_1 pregnancy (1050)
	\square_2 lost to follow up
	□₃ an asthma-related adverse event
	☐ ₄ a medication-related adverse event
	$oldsymbol{\square}_{5}$ an adverse event not related to asthma or medications
	□ ₆ treatment failure
	□ ₇ other reason*
*Ad	ditional explanation required: (1050D)
Ple	NATURES ase complete the following section regardless of the reason for termination of study ticipation.
corı	rify that all information collected on the AsthmaNet STICS data collection forms for this participant is ect to the best of my knowledge and was collected in accordance with the procedures outlined in the ly protocol.
	(1060) / / 20 (1070)
	(1060)/ (1070) Coordinator Signature (1060)/ / 20 (1070)
	(1080)/ (1090)
	Principal Investigator Signature MM DD YYYY

STICS TREATMENT FAILURE

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed by Interview)

Yellow Zone Follow Up


- Since the last visit or phone contact, did the spirotel device (990) □₁ Yes □₀ No or action plan alert you to start a yellow zone?
 If NO, skip to Q3.
- If Yes, did you start it when alerted? (995) □₁ Yes □₀ No
 2a. If No, what was the reason that you didn't start it? (995D)

(Coordinator Completed)

randomization?

Treatment Failure Assessment

- 3. Has the participant experienced 6 yellow zone courses (1000) \square_1 Yes \square_0 No since randomization?
- 4. Has the participant required 2 courses of prednisone for treatment of asthma within 6 months since randomization? \square_1 Yes \square_0 No
- 5. Has the participant required 3 courses of prednisone for (1020) □₁ Yes □₀ No treatment of asthma within 12 months since
- 6. Has the participant been hospitalized for more than 24 (1030) □₁ Yes □₀ No hours due to an asthma exacerbation?
- 7. Is the participant a treatment failure? If any of the shaded (1040) \square_1 Yes boxes is selected, the participant is a treatment failure.
 - → If NO, continue with remaining visit procedures.
 - → If YES, record the treatment failure date. Complete the STICS Termination of Study Participation (P7_TERM) form, STICS Study Treatment Questionnaire (P7_CC_TXQX, P7_PART_TXQX) forms, and collect study medications and supplies as soon as possible.
- 8. Date treatment failure occurred. (1050) ____/





TREATMENT FAILURE

Part. ID:	 	 	
Visit:			

COM	MENTS: (6000)				
-					
-					

YELLOW ZONE PHONE ASSESSMENT

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Parent/Guardian Interview Completed)

asthma symptoms?

in 24 hours for relief of asthma symptoms?

Update the STICS Prednisone and Yellow Zone Tracking (P7_TRK) form and complete a Treatment Failure (P7_TRTFAIL) form, if necessary.

- 1. When was the Yellow Zone started? (1000) ____ / ___ / 20____
- 2. Did you start the Yellow Zone in the morning or the evening? \square_1 AM \square_2 PM evening?
- 3. Why was the Yellow Zone started? ☐₁ Albuterol given two times (4 puffs) in 6 hours
 - Albuterol given three times (6 puffs) in 24 hours
 - ☐₃ A nighttime awakening with albuterol use
 - Other (please describe)
 (1020D)
- 4. Is the participant still having asthma symptoms? (1030) □₁ Yes □₀ No
 → If NO, Skip to Q5.
 - 4a. Has the participant used more than 3 nebulizer treatments with albuterol or 6 puffs of albuterol (3 treatments of 2 puffs each) in 4 hours for relief of
 - 4b. Has the participant used 12 or more puffs of albuterol (1050) □₁ Yes □₀ No
 - 4c. Has the participant had nighttime awakenings on 2 (1060) □₁ Yes □₀ No
 - out of 3 consecutive nights due to cough, shortness of breath, chest tightness, or wheezing and used albuterol?
 - 4d. Has the participant used 8 or more puffs of albuterol per day on 2 out of 3 consecutive days for relief of asthma symptoms?

 (1070) □₁ Yes □₀ No
 - → If 4a, 4b, 4c, or 4d is 'Yes', the participant may meet criteria for starting prednisone. The study physician should be consulted.
 - → Parent should be instructed to contact the site if the participant continues to meet yellow zone criteria at the end of the 7 day yellow zone period.

YELLOW ZONE PHONE ASSESSMENT

Part. ID:	 	 	
Visit:			

5.	Have you been completing the spirotel® Diary daily?	(1080) \square_1 Yes	\square_0 No
	→ If NO, please review adherence with the parent	. , .	Ü

- 6. Was a nasal sample collected? (1090) □₁ Yes □₀ No → If **NO**, instruct the parent/guardian to collect a nasal
 - sample immediately.

 6a. If **YES**, date nasal sample was collected?

 (1100) ____ / ___ / 20____
 MM __DD __YYYY

COM	IMENTS: (6000)			

CLINICAL ADVERSE EVENTS

Part. ID:
Part. Initials:
Visit:

(Coordinator completed)

Complete this log if the participant experienced any clinical adverse events (including intercurrent events) since the last visit. Check the "None" box if the participant has not experienced any clinical adverse events since the last visit.

$ ightharpoonup_0$ Notice											
* Please complete a Serious A Reporting (SERIOUS) form. ** Please complete the appropriate Medications form. *** Please complete the Concommedications (CMED) form.	oriate Change in	2. DATE STARTED (Top Line) (1020	(1040)	5. TYPE (1050)	6. SEVERITY (1060)	7. SERIOUS (1070)	8. LIKELIHOOD OF RELATIONSHIP TO STUDY DRUG(S) (1080)	9. CHANGE IN STUDY DRUG(S) (1090)	10. OUTCOME (Skip if #3 is missing.) (1100)	11. TREATMENT REQUIRED (1110)	1120)
		3. DATE STOPPED (Bottom Line) (1030	ONGOING at current visit (1040)	INTERMITTENT CONTINUOUS	MILD MODERATE SEVERE	YES* NO	. NONE . UNLIKELY (REMOTE) . POSSIBLE . PROBABLE	.UNCHANGED ALTERED**	1 - COMPLETELY RECOVERED 2 - RECOVERED, BUT WITH LASTING EFFECTS 3 - DEATH*	NONE - MEDICATION*** - HOSPITALIZATION* - OTHER	ONGOING at final visit (1120)
DESCRIPTION OF ADVERSE EVENT (1000)	1. ICD9 CODE (1010)	MONTH / DAY / YEAR	4.	1 2	4 2 8	1 0	-αε4 	- 2 - 4	4 Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	- 0 c 4	12.
		//20	_ 🗖								
		//20	— 1								_ 1
		//20	- 🗖								
		//20									
		//20									
		//20									
		//20	- D 1								
		//20									_ 1
		//20	_ _								
		//20									j

PEDIATRIC ASTHMA AND ALLERGY HISTORY

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed by Interview)

•		HISTORY							
1.		oximately how old was the participant when t symptoms suggesting asthma first appeared?	(1000-1010)		years		_ month	าร	
2.	Has asthi	a doctor diagnosed the participant with ma?	(1065)		Yes	\square_0	No		
	2a.	If YES , how old was the participant when a doctor first diagnosed him/her with asthma?	(1070-1080)		years		_ month	ns	
3.	relati asthi	e any of the participant's immediate blood ives been told by a physician that they have ma? (Check the 'N/A' box if the participant is not have biological siblings or children.)							
		Mother	(1090)		Yes	\square_0	No	□8	Don't Know
	3b.	Father	(1100)		Yes	\Box_0	No	□8	Don't Know
	3c.	Brother(s) or Sister(s)	(1110)		Yes No Don't Kr N/A	now			
	3d.	Child(ren)	(1120)		Yes No Don't Kr N/A	now			
AST	НМА	SYMPTOMS		9	14// (
4.	How do you categorize the participant's asthma symptoms throughout the course of the year? → If 'Vary by season(s)', do the participant's		(1130)		Relative Vary by	-		all y	ear
	4a.	asthma symptoms worsen during the Winter?	(1140)		Yes	\Box_0	No		
	4b.	Spring?	(1150)		Yes		No		
	4c.	Summer?	(1160)		Yes		No		
	4d.	Fall?	(1170)		Yes	\Box_0	No		

PEDIATRIC ASTHMA AND ALLERGY HISTORY

5.		In the last 12 months, how many <i>(Enter '00' if</i> none)											
		Asthma episodes has the participant had that required emergency care or an unscheduled office visit?	(1180)	episodes									
	5b.	Overnight hospitalizations has the participant had due to asthma?	(1190)	hospitalizations									
	5c.	Courses of systemic corticosteroid therapy (e.g., prednisone, IM, IV) for asthma has the participant taken?	(1200)	courses									
	5d.	Days of work, school/daycare, or housework has the participant missed due to asthma? → If Q5d > 0, complete Q5di.	(1210)	days									
		5di. In the past 3 months, how many days of work, school/daycare, or housework has the participant missed due to asthma?	(1220)	days									
	5e.	Days of work, school, or housework has the participant's parent/guardian or another caretaker missed because of the participant's asthma symptoms? → If Q5e > 0, complete Q5ei.	(1230)	days									
		5ei. In the past 3 months, how many days of work, school, or housework has the participant's parent/guardian or another caretaker missed due to asthma?	(1240)	days									
6.		the participant ever been admitted to an nsive care unit for asthma? If NO , skip to Q7.	(1250)	□ ₁ Yes □ ₀ No									
	6a.	How many times has the participant been admitted to an intensive care unit for asthma?	(1260)										
	6b.	Has the participant ever had invasive mechanical ventilation?	(1270)	\square_1 Yes \square_0 No	☐ ₈ Don't Know								
	6c.	Has the participant ever had non-invasive mechanical ventilation?	(1280)	□₁ Yes □₀ No	☐ ₈ Don't Know								

PEDIATRIC ASTHMA AND ALLERGY HISTORY

Part. ID:	 	 	 _
Visit:			

ASTHMA TRIGGERS

7.		any of the following currently provoke the icipant's asthma?				
	7a.	Exercise/Sports/Play	(1290)	□ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	7b.	Menstrual cycle (If participant is male or a pre-menarche female, leave blank.)	(1300)	☐ ₁ Yes	□ ₀ No	☐ ₈ Don't Know
	7c.	Aspirin or non-steroidal anti-inflammatory drugs (e.g., Aleve, Motrin)	(1310)	□₁ Yes	□ ₀ No	□ ₈ Don't Know
	7d.	Respiratory infections (e.g., colds)	(1320)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
	7e.	Irritants (e.g., pollution, odors, perfumes, chemicals, household cleaners)	(1330)	□ ₁ Yes	□ ₀ No	□ ₈ Don't Know
	7f.	Weather conditions (e.g., change in weather, humidity)	(1340)	□ ₁ Yes	□ ₀ No	□ ₈ Don't Know
	7g.	Exposure to cold air	(1350)	□₁ Yes	\square_0 No	□ ₈ Don't Know
	7h.	Emotional factors (e.g., stress, laughing)	(1360)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
	7i.	Tobacco smoke	(1370)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
	7j.	Food additives/preservatives (e.g., MSG, sulfites)	(1380)	□ ₁ Yes	□ ₀ No	☐ ₈ Don't Know
	7k.	Allergies (e.g., dust, animals, pollens)	(1390)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
	7I.	Other	(1400)	□₁ Yes	\square_0 No	
		If YES , please specify	(1400D)			
ALI	ERG	BIES				
8.		which of the following did a doctor or other lth practitioner say the participant was allergic?				
	8a.	Medicines	(1410)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
		If YES , please list:	(1410D)			



PEDIATRIC ASTHMA AND ALLERGY HISTORY

Part. ID:	 	 _	 _	
Visit:				

	8b.	Foods	(1420)	□₁ Yes	\square_0 No	□ ₈ Don't Know
		If YES , please list:	(1420D)			
	8c.	Things the participant breathes in or is exposed to (e.g., dust, pollens, molds, animal fur, feathers, dander)	(1430)	□ ₁ Yes	□ ₀ No	□ ₈ Don't Know
	8d.	Stinging insects such as bees or wasps	(1440)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	8e.	Latex	(1450)	□₁ Yes	\square_0 No	☐ ₈ Don't Know
	8f.	Other	(1460)	□₁ Yes	\square_0 No	
		If YES , describe:	(1460D)			
9.		the participant ever had eczema / atopic natitis (i.e., prolonged itchy, scaly skin rash)? If NO or DON'T KNOW , skip to Q10.	(1470)	☐ ₁ Yes	□ ₀ No	☐ ₈ Don't Know
	9a.	At what age did the participant FIRST have eczema?	(1480-1490)	year	rs mon	ths
	9b.	Was the eczema diagnosed by a doctor?	(1500)	□₁ Yes	\square_0 No	
	9c.	During the past 12 months, how would you generally describe the participant's eczema? → If <i>NONE</i> , skip to Q10.	(1510)	\square_1 None \square_2 Mild \square_3 Moder \square_4 Severe		
	9d.	Which parts of the participant's body were ever affected by eczema in the past 12 months?				
		9di. Head	(1520)	□₁ Yes	\square_0 No	
		9dii. Arms/Hands	(1530)	☐ ₁ Yes	\square_0 No	
		9diii. Trunk (mid-section or torso)	(1540)	☐ ₁ Yes	\square_0 No	
		9div. Legs/Feet	(1550)	□₁ Yes	\square_0 No	

PEDIATRIC ASTHMA AND ALLERGY HISTORY

Part. I	D:	 	 _	 	_
Visit: _					

	9dv. Other	(1560)	□₁ Yes	□ _o No	
	If VEO who are a was if y	. ,	·		
10.	If YES , please specify Have any of the participant's immediate blood relatives been told by a physician that they have allergies/eczema/hay fever? (Check the 'N/A' box if the participant does not have biological siblings or children.)	(1560D)			
	10a. Mother	(1570)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
	10b. Father	(1580)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	10c. Brother(s) or Sister(s)	(1590)	□ ₁ Yes □ ₀ No □ ₈ Don't I □ ₉ N/A	Know	
	10d. Child(ren)	(1600)	☐ ₁ Yes ☐ ₀ No ☐ ₈ Don't I ☐ ₉ N/A	Know	
SMC	OKING HISTORY				
11.	Did the participant's mother smoke while she was pregnant with the participant? → If NO or DON'T KNOW , skip to Q13.	(1610)	□ ₁ Yes	□ ₀ No	□ ₈ Don't Know
12.	During which part(s) of the pregnancy did the participant's mother smoke?				
	12a. First 3 months	(1620)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	12b. Middle 3 months	(1630)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	12c. Last 3 months	(1640)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
13.	Between the time the participant was born and when he/she turned 5 years of age, or present if less than 5 years of age, were there any smokers in any household in which the participant spent time? (Include any households the participant regularly spent time in.) If NO or DON'T KNOW, skip to Q14.	(1650)	□₁ Yes	□ ₀ No	□ ₈ Don't Know



PEDIATRIC ASTHMA

Part. ID:	 	 	 	
Visit:				

	13a. Did the participant's mother (or stepmother or	((222)	□ Vee	□ No	Dan't Know
	female guardian) smoke?	(1660)	□₁ Yes	\square_0 No	山 ₈ Don't Know
	13b. Did the participant's father (or stepfather or male guardian) smoke?	(1670)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	13c. Were there any other smokers in the household?	(1680)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
14.	At the present time, are there any smokers in any household in which the participant spends time? (Include any households the participant regularly spends time in.) If NO or DON'T KNOW, STOP HERE.	(1690)	□ ₁ Yes	□ ₀ No	□ ₈ Don't Know
	14a. Does the participant's mother (or stepmother or female guardian) smoke?	(1700)	☐ ₁ Yes	\square_0 No	☐ ₈ Don't Know
	14b. Does the participant's father (or stepfather or male guardian) smoke?	(1710)	☐ ₁ Yes	\square_0 No	□ ₈ Don't Know
	14c. Are there any other smokers in the household?	(1720)	□ ₁ Yes	□ ₀ No	☐ ₈ Don't Know
COI	MMENTS: (6000)				

FOR ASTHMA/ALLERGY AND ADVERSE EVENTS

Part. ID:
Part. Initials:
Visit:

(Coordinator completed)

Instructions: Since signing the informed consent or last study visit, list all prescription and over-the-counter (OTC) concomitant medications used to treat asthma/allergy symptoms and adverse events. Do not list routine use of study drugs or rescue medications. Check the "None" box if the participant has not started taking any medications since signing the informed consent or last study visit. If the medication is not related to an adverse or laboratory event, leave the event number missing and check the "N/A" box. If the participant is still taking the medication at the end of the current visit, check the "ongoing at current visit" check box and leave the stop date missing. All ongoing medications should be reviewed at subsequent visits to document the stop date of a medication. At the last study visit or an early termination visit, review all ongoing medication and indicate a stop date or check the "ongoing at final visit" check box on the data collection forms and update the medication data in the AsthmaNet data entry application.

At the final study visit or early termination visit, forward all concomitant medications for asthma/allergy and adverse event-related medications forms to the DCC.

□ ₀ None										
NAME OF MEDICATION (1000)	CODE (1010)	RELATED EVENT (1020)	DOSE (1030)	SLINN (1040)	FREQUENCY	ROUTE (1055)	START DATE (MM/DD/YYYY) (1060)	STOP DATE (MM/DD/YYYY) (1070)	ONGOING AT CORRENT VISIT	ONGOING AT
		Event					_/_/	_/_/		□₁
		Event					//	//		
		Event					_/_/	_/_/		
		Event					//	//		
		Event					_/_/	//		□₁
		Event						//		



Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Co	ordinator Completed by Interview)					
	e: If you are a parent or guardian responding for a child icipant.	d, "you" i	s ref	erring to t	he child who	is the study
1.	Who is the respondent?	(1000) (1000D)	□₂ Parent/Guardian□₃ Other (specify)			
GEN	IERAL HOUSE CHARACTERISTICS					
('Ho	use' is meant to refer to the place where you live n	nost of	the t	ime.)		
2.	How long have you lived in the current house? (Estimate if uncertain.)	(1010-1020))	years	montl	ns
3.	Does your house use a wood burning stove as a primary source of heat?	(1030)		1 Yes	□ ₀ No	☐ ₈ Don't Know
4.	Does your house use an air conditioner?	(1040)		1 Yes	□ ₀ No	☐ ₈ Don't Know
5.	Does your house use an evaporative cooler (swamp cooler)?	(1050)		1 Yes	□ ₀ No	□ ₈ Don't Know
6.	Does your house use a humidifier? (Include humidifier built into the heating system of your house.)	(1060)		1 Yes	□ _o No	□ ₈ Don't Know
7.	Does your house use a dehumidifier? (Include dehumidifier built into the cooling system of your house.)	(1070)		1 Yes	□ ₀ No	☐ ₈ Don't Know
8.	Has there been water damage to your house, basement, or its contents during the past 12 months?	(1080)		1 Yes	□ ₀ No	☐ ₈ Don't Know
9.	Has there been any mold or mildew, on any surfaces, inside your house in the past 12 months? → If NO or DON'T KNOW, skip to Q11.	(1090)		1 Yes	□ ₀ No	☐ ₈ Don't Know
10.	Which rooms have or have had mold or mildew?					
	10a. Bathroom(s)	(1100)		₁ Yes	□ ₀ No	

Part. ID:	 	 	
√isit:			

	10b. Basement or attic	(1110)	☐ ₁ Yes	□ _o No
	10c. Kitchen	(1120)	□₁ Yes	□ _o No
	10d. Your bedroom	(1130)	□₁ Yes	□ _o No
	10e. Other bedrooms	(1140)	□₁ Yes	□ _o No
	10f. Living or family room	(1150)	☐ ₁ Yes	□ _o No
	10g. Other	(1160)	☐ ₁ Yes	□ _o No
	If YES , please specify	(1160D)		
11.	Do you ever see cockroaches in your house? → If <i>NO</i> , skip to Q13.	(1170)	□ ₁ Yes	□ ₀ No
12.	In which room(s) have you seen cockroaches?			
	12a. Kitchen	(1180)	□₁ Yes	□ _o No
	12b. Basement or attic	(1190)	☐ ₁ Yes	□ _o No
	12c. Bathroom(s)	(1200)	☐ ₁ Yes	□ _o No
	12d. Living or family room	(1210)	☐ ₁ Yes	□ _o No
	12e. Your bedroom	(1220)	☐ ₁ Yes	□ _o No
	12f. Other bedrooms	(1230)	☐ ₁ Yes	□ _o No
	12g. Garage	(1240)	□₁ Yes	□ ₀ No
	12h. Other	(1250)	□₁ Yes	□ ₀ No
	If YES , please specify	(1250D)		
	Do you ever see rodents (mice, rats) or rodent droppings in your house? → If <i>NO</i> , skip to Q15.	(1260)	☐ ₁ Yes	□ ₀ No
14.	In which room(s) have you seen rodents or rodent droppings?			
	14a. Kitchen	(1270)	☐ ₁ Yes	□ ₀ No
	14b. Basement or attic	(1280)	☐₁ Yes	□ _o No
	14c. Bathroom(s)	(1290)	□₁ Yes	□₀ No

Part. ID:	 	 	-	 	
Visit:					

	14d. Living or family room	(1300)		Yes	□ _o No
	14e. Your bedroom	(1310)		Yes	□ _o No
	14f. Other bedrooms	(1320)		Yes	□ ₀ No
	14g. Garage	(1330)		Yes	□ ₀ No
	14h. Other	(1340)		Yes	□ ₀ No
	If YES, please specify	(1340D)			
15.	Are any of the following located on your property or no	ext to yo	ur pro	perty?	
	15a. Barns	(1350)		Yes	□ _o No
	15b. Hay	(1360)		Yes	□ _o No
	15c. Woodsheds	(1370)		Yes	□ _o No
	15d. Firewood	(1380)		Yes	□ _o No
	15e. Chicken coops	(1390)		Yes	□ _o No
	15f. Corral	(1400)		Yes	□ _o No
	ARACTERISTICS OF THE PARTICIPANT'S BEDROC ne participant does not have a bed or bedroom, answer		olace	where th	ne participant sleeps.)
16.	What is the floor covering in your bedroom?	(1410)	$ \begin{array}{c} \square_2 \\ \square_3 \\ \square_4 \end{array} $	Rug/carp Vinyl tile Wood Ceramic Other (s	or linoleum
		(1410D)	 9	Don't kn	ow
17.	What type of mattress is on your bed? → If <i>NONE</i> , skip to Q19.	(1420)	$ \begin{array}{c} \square_2\\ \square_3\\ \square_4\\ \square_5 \end{array} $	None Inner sp Foam m Waterbe Air mattr Other (s	ed ress
		(1420D)		Don't kn	 ow



Part. ID:	-	 	 -	 	
Visit:					

18.	Is the mattress completely enclosed in ar proof, encasing cover?	n allergy	/-	(1430)		Yes		₀ No		
19.	Does your bed have a box spring? → If <i>NO</i> , skip to Q21.			(1440)		Yes		₀ No		
20.	Is the box spring completely enclosed in a proof, encasing cover?	an aller	gy-	(1450)		Yes		_o No		
21.	What type of pillow do you usually sleep → If <i>NONE</i> , skip to Q23.	with?		(1460)	\square_2	Foa	e ther/do m/Dacr er (spec	on/syn	thetic	
				(1460D)			't know			
22.	Is the pillow completely enclosed in an al proof, encasing cover?	lergy-		(1470)		Yes		₀ No		
PET	s									
23.	Does your household have any pets? → If <i>NO</i> , skip to Q25.			(1480)		Yes		₀ No		
24.	Enter the number of pets that the househ next question.)	old has	. (Ente	r '00' if	none	e. If	none to	Q2 <i>4a</i>	– Q24d,	skip to the
	24a. Cat	(1490)		(15	00)		Indoor		Outdoor	\square_3 Both
	24b. Dog	(1510)		. (15	20)		Indoor		Outdoor	\square_3 Both
	24c. Rabbit, guinea pig, hamster, gerbil, or mouse	(1530)		. (15	40)		Indoor		Outdoor	□ ₃ Both
	24d. Bird	(1550)		. (15	60)		Indoor		Outdoor	☐ ₃ Both
25.	In general, and on a regular basis, are yo to any of the following animals?	u expo	sed							
	25a. Cat			(1570)		Yes		₀ No		
	25b. Dog			(1580)		Yes		₀ No		
	25c. Rabbit, guinea pig, hamster, gerbil,	or mous	se	(1590)		Yes		₀ No		
	25d. Bird			(1600)		Yes		₀ No		
	25e. Farm animals			(1610)		Yes		₀ No		

Part. ID:	 	 	
Visit:			

	25f.	Other	(1620)	□₁ Yes	□ ₀ No
		If YES , please specify	(1620D)		
→	-	nrticipant is 6 years of age or older, STOP HERI complete the source documentation box.	E		
DAY	CAR	RE			
26.		he participant attend day care during the 1 st of life?	(1630)	☐ ₁ Yes	□ ₀ No
	26a.	If YES , at what age did the day care attendance begin?	(1640)	month	os .
27.	Does →	s the participant currently attend day care? If No, STOP HERE and complete the source documentation box.	(1650)	□ ₁ Yes	□ ₀ No
	27a.	Is the day care	(1660)	\square_1 In home \square_2 Nonreside \square_3 Mixed	•
	27b.	How many children are in the participant's day care room?	(1670)	childre	en
	27c.	How many hours per day is the participant at day care?	(1680)	hours	
	27d.	How many days per week is the participant at day care?	(1690)	days	
	27e.	How many months per year is the participant at day care?	(1700)	month	ıs
			Partio	cipant/Guardi	an Source Documentation
			Partio	cipant/Guardi	an Initials: (1710)
			Date	:/ MM DD	/ 20 (1720)
		ntor Completed			
(6000)	/MEN):	ITS			



HOUSEHOLD SOCIO-ECONOMIC INFORMATION

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Parent/Legal Guardian or Participant Completed)

Please answer the following questions about your primary household. If you're a college student living away from home during the school year, the questions pertain to your parents' household.

1.	Who is the respondent?	(1000)	 □₁ Self/Participant □₂ Parent/Guardian □₃ Other (specify)
		(1000D)	
2.	Which category best describes the highest grade or educational level that any member of your household has achieved? (Check one box only.)	(1010)	□₀ No High School diploma □₁ GED □₂ High School diploma □₃ Technical training □₄ Some college, no degree □₅ Associate degree □₆ Bachelors degree □٫ Masters degree □٫ Masters degree □٫ Mol/PhD/JD/PharmD □٫ Decline to answer □₁₀ Don't know
3.	To help us characterize the economic status of our study participants, please indicate which category best describes the combined annual income , before taxes, of all members of your household for the last year. (Check one box only.)	(1020)	☐ ₁ Less than \$25,000 ☐ ₂ \$25,000 - \$49,999 ☐ ₃ \$50,000 - \$99,999 ☐ ₄ \$100,000 or more ☐ ₉ Decline to answer ☐ ₁₀ Don't know
4.	How many people (adults and children) are supported by this income reported in Q3?	(1030)	people
CO	MMENTS: (6000)		

PEDIATRIC LONG PHYSICAL EXAM

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

•			completed) EIGHT – First study visit only or until both are c	completed	ı	
1.	Biological mother's height (complete height or check unknown)		5 \ 1	(1000-1010)	feet	inches
		•		(1020)	\square_9 Don't	Know
2.	Biolo unkn	_		(1030-1040)	feet	inches
				(1050)	□ ₉ Don't k	Know
PAR	TICIF	PANT	MEASUREMENTS – Complete at all applicable	study vis	sits	
3.	Wha	it type	e of height measurement was obtained?	(1060)	□₁ Standi □₂ Length	•
	3a.	First	measurement	(1070)		cm
	3b.	Seco	ond measurement	(1080)		cm
	3c.	Third	d measurement	(1090)		cm
	3d.	Aver	age height or length measurement	(1100)		cm
		→	Plot average height or length on gender- and a study MOP for further details.	age-appro	priate gro	wth charts. See
	3e.	•	our judgment, was the participant's height or the measurement acceptable?	(1110)	□₁ Yes	\square_0 No
		3ei.	If NO , why was it unacceptable? (1120D)			
4.	Weig	ght (s	hoes off, light clothing)	(1130)		kg
	→	Plot deta	weight on gender- and age-appropriate growth ils.	charts. S	See study	MOP for further
ORA	L CA	ANDII	DIASIS			
5.	Does		participant have evidence of oral candidiasis? ES, complete the Clinical Adverse Events	(1140)	□₁ Yes	\square_0 No

(AECLIN) form.

6.

Hair and Skin

PEDIATRIC LONG PHYSICAL EXAM

Part. ID:	 	 	
Visit:			

DO NOT DATA ENTER THE INFORMATION ON THE REST OF THE FORM EXCEPT THE COMMENTS (IF APPLICABLE)

(Licensed Medical Practitioner Completed)

Please indicate current physical findings by checking the appropriate boxes below. If ABNORMAL, please describe concisely.

Normal Abnormal

Not Done

7.	Lymph nodes									
8.	Eyes (excluding corrective lenses)									
9.	Ears, Nose, and Throat									
10.	Respiratory									
	10a. If Abnormal:				 Wheeze on inspiration or expiration Adventitious sounds other than wheezing Other 					
11.	Cardiovascular									
12.	Gastrointestinal									
13.	Musculoskeletal									
14.	Neurological									
15.	Mental Status									
16.	Other(check Not Done if non-application	ble)								
		Licensed Medical Practitioner Source Documentation Licensed Medical Practitioner Signature: Printed Name: Date: / / 20 MM								

PEDIATRIC LONG PHYSICAL EXAM

Part. ID:	 	
Visit:		

CON	MENTS: (6000)			

PRIOR CONDITIONS FOR ALL PARTICIPANTS

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed by Interview)

Note: If you are a parent or guardian responding for a child, "you" is referring to the child who is the study participant.

1.	Who	is the respondent?			(1	000)	 □₁ Self/Participant □₂ Parent/Guardian □₃ Other (specify) 		
					(1	000D)	——————————————————————————————————————		
PRI	OR D	ISEASES, ILLNESSES, AND S	SURGE	RIES					
Hav	Have you had any diseases, illnesses, conditions, or surgeries related to the following areas?								
							If Yes, Comment		
2.	Skin		(1010)	□ ₁ Yes	\square_0 No	(1010	D)		
3.	Ears	s, Nose, or Throat							
	За.	Have you ever had allergic rhinitis (hay fever)?	(1020)	□₁ Yes	□ ₀ No	 9	Don't know		
	3b.	Have you ever had nasal polyps?	(1030)	□₁ Yes	□ ₀ No	 9	Don't know		
	3c.	Do you have chronic or recurrent sinusitis (treated with antibiotics and/or surgery)?	(1040)	□ ₁ Yes	□ ₀ No	 9	Don't know		
	3d.	Have you ever been diagnosed with vocal cord dysfunction?	(1050)	□₁ Yes	□ ₀ No	 9	Don't know		
	3e.	Have you ever had other conditions related to the ear, nose, or throat?	(1060)	☐ ₁ Yes	□ ₀ No	(1060	D)		
4.	Lung	g - other than asthma							
	4a.	Have you ever had pneumonia?	(1070)	□₁ Yes	□ ₀ No	\square_9	Don't know		

PRIOR CONDITIONS FOR ALL PARTICIPANTS

Part. ID:	 	 	-	 	
/isit:					

								If Yes, Comment
		4ai.	If YES , were you diagnosed by chest x-ray?	(1080)		Yes	□ ₀ No	□ ₉ Don't know
		4aii.	If YES , were you treated with antibiotics?	(1090)	\square_1	Yes	□ ₀ No	□ ₉ Don't know
	4b.		e you ever had nchitis?	(1100)		Yes	□ ₀ No	□ ₉ Don't know
	4c.	cond	e you ever had other ditions related to the is (besides asthma)?	(1110)		Yes	□ ₀ No	(1110D)
5.	Stor	mach	or Intestines					
	5a.	gast	you have troesophageal reflux ase (GERD)?	(1120)		Yes	□ ₀ No	□ ₉ Don't know
	5b.	cond	e you ever had other ditions related to the nach or intestines?	(1130)		Yes	□ ₀ No	(1130D)
6.	Slee	ep Dis	sorder					
	6a.	with	e you been diagnosed sleep disordered athing (sleep apnea)?	(1150)		Yes	□ ₀ No	(1150D)
		6ai.	If YES , are you being treated with CPAP or BiPAP?	(1160)		Yes	□ ₀ No	
	6b.		e you ever had other p disorders?	(1170)		Yes	□ ₀ No	(1170D)
7.	cond	ditions	ever had other s that have not been d on this form?	(1180)		Yes	□ ₀ No	(1180D)
COI	име	NTS:	(6000)					

PRIOR ASTHMA/ALLERGY TREATMENT

(Coordinator Completed by Interview)

Note: If you are a parent or guardian responding for a child, "you" is referring to the child who is the study participant.

1.	Who is the respondent?	(1000) \square_1 Self/Participant
		□₂ Parent/Guardian
		\square_3 Other (specify)
		(1000D)

Next I will read a list of medications that are used to treat asthma and allergies. Please indicate if you have used each medication *during the past 12 months FOR ASTHMA OR ALLERGIES*. If you have used a particular medication, please indicate to the best of your knowledge the date it was last taken.

med	ng the past 12 months were the following lications used FOR ASTHMA OR ERGIES?		If Yes, indicat medication w Month / Day /	as last taken
2.	Short-acting Inhaled Beta-Agonists by Inhaler (e.g., albuterol, Primatene Mist, Maxair, ProAir, Proventil, Ventolin, Xopenex)	(1010)	\square_1 Yes \square_0 No \square_9 Don't Know	20
	2a. If YES , indicate average weekly puffs in the past month (Enter '000' if none used)	(1050)	weekly puffs	
3.	Rescue treatment via a Nebulizer Machine (e.g., albuterol, ipratropium, Combivent, Xopenex, levalbuterol)	(1060)	\square_1 Yes (1070) / (1080) /	20 (1090)
4.	Long-acting Inhaled Beta-Agonists (e.g., Serevent, Foradil, salmeterol, formoterol) → Do not consider combination medications.	(1100)	\square_1 Yes $\qquad \qquad {(1110)}/{(1120)}/$ \square_9 Don't Know	(1130)
5.	Oral Beta-Agonists (e.g., albuterol, Brethine, Bricanyl, metaproterenol, Proventil, Ventolin, Repetabs, Volmax)	(1140)	\square_1 Yes \square_0 No \square_9 Don't Know	20

PRIOR ASTHMA/ALLERGY TREATMENT

Part. ID:	 	
Visit:		

6.	Oral Theophylline (short-acting or sustained release) (e.g., Aminophylline, Slo-Phyllin, Slo-bid, Theo-Dur, Uniphyl)	(1180)		Yes No Don't Know	(1190) / (1200) / 20
					If Yes, indicate date medication was last taken Month / Day / Year
7.	Inhaled Anticholinergic by Inhaler (e.g., Atrovent, Combivent, Spiriva)	(1220)		Yes No Don't Know	(1230) / <u>(1240)</u> / 20
8.	Leukotriene Antagonist / 5LO Inhibitors (e.g., Accolate, Zyflo, Singulair)	(1260)		Yes No Don't Know	(1270) / / 20 (1280) (1290)
9.	IgE Blocker (e.g., Xolair)	(1300)		Yes No Don't Know	(1310) / <u></u> / 20 <u></u> (1330)
10.	Oral Steroids FOR ASTHMA (e.g., Prednisone, Prelone, Pediapred, Medrol, Orapred, Decadron, dexamethasone)	(1340)	□ ₁ □ ₀ □ ₉		(1350) / <u>(1360)</u> / 20
	10a. If YES , in the past 12 months, how many consteroids by mouth have you taken FOR AS		of	(1380)	\square_1 1 course \square_2 2 courses \square_3 3 courses \square_4 4 courses \square_5 5 courses \square_6 More than 5 courses
11.	Injectable Steroids FOR ASTHMA (e.g., Medrol, Solumedrol, Decadron, dexamethasone, triamcinolone, Kenalog, hydrocortisone IV)	(1390)		Yes No Don't Know	(1400) / <u>(1410)</u> / 20

PRIOR ASTHMA/ALLERGY TREATMENT

Part. ID:	 	
Visit:		

12.	(e.g.	oids by Inhaler ., Asmanex Twisthaler, QVAR, Flovent, micort Flexhaler) Do not consider combination medications. If YES, complete Q12a – Q12c	(1430)		Yes No Don't Know	(1440) / (1450)	/ 20 (1460)
	12a.	Indicate most recent type of inhaled steroid (refer to PRIOR_TRT_CARD reference care			(1470)	code	
		12ai. If Other, specify the name of the medi	cation		(1470D)		
	12b.	Indicate number of daily puffs used			(1480)	daily puffs	
	12c.	Indicate the total number of months that you inhaled steroid out of the past 12 months	used t	the	(1490)	months	
						If Yes, indica medication w Month / Day /	as last taken
13.	(e.g.	oids by Nebulizer , Pulmicort Respules, budesonide) If YES , complete Q13a – Q13c	(1500)			$\frac{1}{(1510)} / \frac{5}{(1520)}$	
	13a.	Indicate most recent type of nebulized stero (refer to PRIOR_TRT_CARD reference care		n	(1535)	code	
		13ai. If Other, specify the name of the medi	cation		(1500D)		
	13b.	Indicate number of daily treatments used			(1540)	daily treatme	ents
	13c.	Indicate the total number of months that you nebulized steroid out of the past 12 months		the	(1550)	months	
14.	Com	g-Acting Beta-Agonist and Inhaled Steroid abination Medications ., Advair Diskus, Symbicort MDI, Dulera) If YES, complete Q14a – Q14c	(1560)	\Box_1 \Box_0 \Box_9		(1570) / (1580)	/ 20 (1590)
	14a.	Indicate most recent type of combination m taken (refer to PRIOR_TRT_CARD reference			(1600)	code	
		14ai. If Other , specify the name of the medi	cation		(1600D)		
	14b.	Indicate number of daily puffs used			(1610)	daily puffs	
	14c.	Indicate the total number of months that you combination medication out of the past 12 r		the	(1620)	months	

PRIOR ASTHMA/ALLERGY TREATMENT

Part. ID:	 	
Visit:		

During the past 12 months were the following nasal treatments used FOR ALLERGIES?

- 15. Nasal Steroids
 (e.g., Beconase, Vancenase, Flonase,
 Nasacort, Nasalide, Nasarel, Omnaris,
 Rhinocort, Nasonex)
- Non-steroidal Anti-allergic Nasal Medications (e.g., Nasalcrom, Astelin, Astepro, ipratropium)
- (1630) \square_1 Yes \square_0 No
 - Don't Know

Know

Know

- (1670) \square_1 Yes \square_0 No \square_9 Don't

<u>(1640)</u> / <u>(1650)</u> / 20 _____

During the past 12 months were the following general allergy treatments used?

- 17. Anti-allergic Oral Medications (e.g., fexofenadine, loratadine, cetirizine, chlorpheniramine)
- (1710) \square_1 Yes \square_0 No \square_9 Don't
- (1720) / (1730) / 20 (1740)

If Yes, indicate date

Month / Day / Year

medication was last taken

During the past 12 months were the following skin treatments used FOR ECZEMA OR ALLERGIES?

(e.g., Hydrocortisone - multiple strengths

18. Topical Steroids – Prescription (e.g., Synalar, Lidex, Dermacin, Fluocinonide)

Topical Steroids – OTC

and products)

- (1750) \square_1 Yes \square_0 No
 - □₀ No □₀ Don't Know

Know

- (1790) \square_1 Yes \square_0 No \square_9 Don't

 $\frac{1}{(1760)} / \frac{1}{(1770)} / \frac{20}{(1780)} - \frac{1}{(1780)}$

PRIOR ASTHMA/ALLERGY TREATMENT

Part. ID:	 	
Visit:		

During the past 12 months were there any OTHER medications used FOR ASTHMA OR ALLERGIES?

20.	Other Medication FOR ASTHMA OR ALLERGIES	(1830)		Yes No Don't Know	(1840) / (1850) / 20
	20a. If YES , specify the name of the medication			(1830D) _	
trea	ing the past 12 months were the following tments used for conditions OTHER THAN THMA?				
21.	Oral Steroids for Conditions Other Than Asthma (e.g., Prednisone, Prelone, Pediapred, Medrol, Orapred, Decadron, dexamethasone)	(1870)	\Box_0	Yes No Don't Know	(1880) / (1890) / 20 (1900)
	21a. If YES , specify indication			(1870D) _	
					If Yes, indicate date medication was last taken Month / Day / Year
22.	Injectable Steroids for Conditions Other Than Asthma (e.g., Medrol, Solumedrol, Decadron, dexamethasone, triamcinolone, Kenalog, hydrocortisone IV)	(1910)	\square_0	Yes No Don't Know	(1920) / (1930) / 20
	22a. If YES , specify indication			(1910D) _	
COI	MMENTS: (6000)				

SERIOUS ADVERSE EVENT REPORTING FORM

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

This form and a final resolution report (including relevant documents) written by the Principal Investigator should be faxed to the DCC at (717) 531-4359 within 72 hours of notification of a serious event. Also fax the Clinical Adverse Events form (AECLIN), the Concomitant Medications for Asthma and Allergies (CMED) form, and any relevant source documents.

1.	Date of Adverse Event	(1000)	/	_ / 20
2.	Description of Adverse Event (ICD9 Code)	(1010)		
	Describe: (1010D)			
3.	Is the participant currently taking study drug? → If <i>NO</i> , skip to Q6.	(1020)	□ ₁ Yes	\square_0 No
4.	Time interval between the last administration of the study drug and the Adverse Event	(1030)		
5.	What was the unit of time for the interval in Question #4?	(1040)	\square_1 Second \square_2 Minute(\square_3 Hour(s) \square_4 Day(s)	s)
6.	Why was the event serious?			
	6a. Fatal event	(1050)	□₁ Yes	\square_0 No
	6b. Life-threatening event	(1060)	□ ₁ Yes	\square_0 No
	6c. Inpatient hospitalization required → If <i>NO</i> , skip to Q6d.	(1070)	□ ₁ Yes	□ ₀ No
	6ai. Admission date	(1080)	/DD	/ 20
	6aii. Discharge date	(1090)	/	/ 20
	6d. Hospitalization prolonged	(1100)	\square_1 Yes	\square_0 No
	6e. Disabling or incapacitating	(1110)	\square_1 Yes	\square_0 No
	6f. Overdose	(1120)	□₁ Yes	\square_0 No

SERIOUS ADVERSE EVENT

Part. ID:	-	 	 -	 	
Visit:					

	If V	ES attack report or send as each as possible				
11.	Was	s an autopsy performed?		☐ Yes	☐ No	
10.	If pa	articipant died, cause of death:				
DO	NOT	ENTER THE FOLLOWING QUESTIONS: FOR REPOR	TING PU	IRPOSES O	NLY.	
9.		s the event possibly, probably, or definitely related to ly participation?	(1250)	□ ₁ Yes	\square_0 No	
8.	Was	s the event expected or unexpected?	(1240)	\square_1 Expect \square_2 Unexp		
(Inv	estiga	ator Completed)				
		If YES, describe:	(1220D)			
	7d.	Other condition or event	(1220)	☐ ₁ Yes	\square_0 No	
		If YES, describe:	(1210D)			
	7c.	Concurrent medication	(1210)	□₁ Yes	□ ₀ No	
	7b.	Withdrawal of study drug(s)	(1200)	□₁ Yes	□ ₀ No	
	7a.	Toxicity of study drug(s)	(1190)	□₁ Yes	□ ₀ No	
7.	Wha	at in your opinion caused the event?				
		If YES , describe:	(1180D)			
	6I.	Other	(1180)	□₁ Yes	□ ₀ No	
	6k.	Pregnancy	(1170)	□₁ Yes	□ ₀ No	□ ₉ N/A
	6j.	Height failure (per protocol MOP)	(1160)	□₁ Yes	□₀ No	
	6i.	Serious laboratory abnormality with clinical symptoms	(1150)	□₁ Yes	□₀ No	
	6h.	Congenital anomaly	(1140)	□₁ Yes	□₀ No	
	6g.	Cancer	(1130)	□₁ Yes	□₀ No	

If YES, attach report or send as soon as possible.

SERIOUS ADVERSE EVENT

Part. ID:	·	
Visit:		

REPORTING INVESTIGATOR:

Please provide a typed summary of the event including: the participant's status in the study, whether study drugs will be continued, follow-up treatment plans, and communication with the treating physicians and participant or participant's parent/guardian.

COMMENTS: (6000)							
Name:							
Signature:							
Date:// 20							

PEDIATRIC SHORT PHYSICAL EXAM

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

PARTICIPANT MEASUREMENTS –	Complete at all	annlicable	etudy	vicite
FARTICIPANT MEASUREMENTS -	Complete at an	applicable	Study	AISITS

1.	Wha	t type of height measurement was obtained?	(1060)	☐₁ Standing height ☐₂ Length
	1a.	First measurement	(1070)	cm
	1b.	Second measurement	(1080)	cm
	1c.	Third measurement	(1090)	cm
	1d.	Average height or length measurement	(1100)	cm
		→ Plot average height or length on gender- and age study MOP for further details.	e-appro	priate growth charts. See
	1e.	In your judgment, was the participant's height or length measurement acceptable?	(1110)	\square_1 Yes \square_0 No
		1ei. If NO , why was it unacceptable? (1120D)		
2.	Weig	ght (shoes off, light clothing)	(1130)	kg
	→	Plot weight on gender- and age-appropriate growth codetails.	harts.	See study MOP for further
ORA	AL CA	ANDIDIASIS		
3.	Does →	s the participant have evidence of oral candidiasis? If YES, complete the Clinical Adverse Events (AECLIN) form.	(1140)	□₁ Yes □₀ No

PEDIATRIC SHORT PHYSICAL EXAM


Part. ID:	 	
Visit:		

DO NOT DATA ENTER THE INFORMATION ON THE REST OF THE FORM EXCEPT THE COMMENTS (IF APPLICABLE)

Please indicate current physical findings by checking the appropriate boxes below. If ABNORMAL, please describe concisely.

4.	Hair and Skin	Not Done	Normal	Abnormal	
5.	Eyes, Ears, Nose, and Throat				
6.	Respiratory				
	6a. If Abnormal:				Wheeze on inspiration or expiration Adventitious sounds other than wheezing Other
		Coordine Printed Date:	nator Signa Name:/	/ 20 	
CO	MMENTS: (6000)				

Part. ID:										
Part. I	nitials:		Visit:	Visit Date:	/ /	Cod	ordinator ID:			
Chil	Childhood Asthma Control Test for children 4 to 11 years old.									
Kno	w the score).								
This tes	This test will provide a score that may help your doctor determine if your child's asthma treatment plan is working or if it might be time for a change.									
How to	take the Childhoo	od Asthma Conf	trol Test							
Step 1		child select the re-	sponse. Complete t	he remaining three			anding the question, own and without let			
Step 2	Write the number of	each answer in the	e score box provided.			If y	our child's score is 19 or	less, it		
Step 3	Add up each score b	oox for the total.			1	ma	ay be a sign that your child the sign of t	d's		
Step 4	Take the test to the o	doctor to talk about	your child's total sco	re.	or I	ess it c	could be. No matter what to bre, bring this test to your talk about your child's res	he doctor		
Have y	our child compl	ete these ques	stions.				,			
1. How is	your asthma today?							SCORE		
	O				2		8			
0.11	Very bad		Bad		Good		Very good			
2. How m	uch of a problem is your	astnma wnen you ru	n, exercise or play spor	IS?		T		1		
	0				2		3			
It's a big	oroblem, I can't do wha	at I want to do. It's	a problem and I don't	like it. It's a little pro	oblem but it's okay.	lt's	s not a problem.			
3. Do you	cough because of your	asthma?				_		-		
	0				2		3			
	Yes, all of the time		Yes, most of the tim	e. Yes, sor	ne of the time.	No,	none of the time.			
4. Do you	wake up during the nigh	nt because of your as	thma?			1		1		
	0				2		3			
	Yes, all of the time) .	Yes, most of the tim	e. Yes, sor	me of the time.	No,	none of the time.			
Please	complete the fo	ollowing guest	ions on your ow	'n.				-		
	•	•	•	y daytime asthma sy	mptoms?					
	6	4	3	2	0		0			
	Not at all	1-3 days	4-10 days	11-18 days	19-24 days		eryday			
6. Durin	g the <u>last 4 weeks</u> , h	ow many days did	d your child wheeze	during the day becar	use of asthma?			-		
	5 Not at all	4 1-3 days	3 4-10 days	2 11-18 days	19-24 days	Ev	O eryday			



EXHALED NITRIC OXIDE

Supervisor ID: __ _ _ _

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

(Technician Completed)

ENO must be performed prior to any pulmonary function testing. Complete this form only if the participant is eligible according to the appropriate Pulmonary Procedure Checklist form.

1.	Has QC procedure been performed on the NIOX MINO® today?	(1000)	☐ ₁ Yes	\square_0 No
	→ If NO , please specify the reason QC was not performed in Q6000.			
2.	Did the participant eat or drink within the past hour?	(1010)	□₁ Yes	□ ₀ No
3.	Did the participant take part in strenuous activity/exercise within the past hour?	(1020)	□ ₁ Yes	□ ₀ No
4.	Time eNO started (based on a 24-hour clock)	(1040)		
5.	ENO Measurement	(1050)	ppl	b
CON	MMENTS: (6000)			

PRE-BRONCHODILATOR IOS

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

(Technician Completed)

Complete this form only if the participant is eligible according to the appropriate Pulmonary Procedure Checklist form.

PRE-BRONCHODILATOR PULMONARY FUNCTION TESTING

1.	Time IOS started (based on 24-hour clock)	(1000)	
Res	ults of first effort		
2.	R_5	(1010)	 kPa/l/s
3.	R ₁₀	(1020)	 kPa/l/s
4.	R ₁₅	(1030)	 kPa/l/s
5.	R ₂₀	(1040)	 kPa/I/s
6.	R ₃₅	(1050)	 kPa/I/s
7.	X_5	(1060)	 kPa/I/s
8.	Resonant Frequency	(1070)	 Hz
9.	Area X _A	(1080)	 kPa/I
Res	ults of second effort		
10.	R ₅	(1090)	 kPa/I/s
11.	R ₁₀	(1100)	 kPa/I/s
12.	R ₁₅	(1110)	 kPa/I/s
13.	R ₂₀	(1120)	 kPa/I/s
14.	R ₃₅	(1130)	 kPa/I/s
15.	X_5	(1140)	 kPa/I/s
16.	Resonant Frequency	(1150)	 Hz
17.	Area X₄	(1160)	kPa/l

PRE-BRONCHODILATOR IOS

Part. ID:	-	 	 -	 	
Visit:					

R	esu	lts	of	thir	d e	ffo	rt

18.	R_5	(1170)			_ kPa/l/s	
19.	R ₁₀	(1180)		·	_ kPa/l/s	
20.	R ₁₅	(1190)		·	_ kPa/l/s	
21.	R ₂₀	(1200)		·	_ kPa/l/s	
22.	R ₃₅	(1210)		·	_ kPa/l/s	
23.	X_5	(1220)		·	_ kPa/l/s	
24.	Resonant Frequency	(1230)		·	_ Hz	
25.	Area X _A	(1240)		·	_ kPa/l	
26.	In your judgment, was the participant's pre-bronchodilator technique acceptable?	(1250)		Yes	□ ₀ No	
	26a. If NO , why was it unacceptable?					
	26ai. Coherence < 0.80 (for R ₁₀)	(1260)		Yes	\square_0 No	
	26aii. Poor repeatability (for R ₁₀ values vary by more than 20%)	(1270)		Yes	\square_0 No	
	26aiii. Fewer than 3 good tests	(1280)		Yes	\square_0 No	
	26aiv. Inconsistent tidal breathing	(1290)		Yes	\square_0 No	
	26av. Participant refusal during test	(1300)		Yes	\square_0 No	
	26avi. Other	(1310)		Yes	\square_0 No	
	If YES, please specify	(1310D)				
	26b. If YES , grade the participant's technique	(1320)	_	•	ble, good effort ble, questionable	9

PRE-BRONCHODILATOR IOS

Part. ID:	-	 	 -	 	
Visit:					

1		C	Sta	-	1~	-	۱,
ı	U	2	Sta	na	a	ra	S

27.	How was the participant positioned?	(1330)	 □₁ Sitting on a chair □₂ Sitting on a lap □₃ Standing □₄ Other
28.	Were the participant's cheeks held?	(1340)	\square_1 Yes \square_0 No
	28a. If YES , how were the participant's cheeks held?	(1350)	 □₁ Parent/guardian held the cheeks □₂ Technician held the cheeks □₃ Participant held his/her own cheeks □₄ Other
29.	Were nose clips used?	(1360)	\square_1 Yes \square_0 No
	29a. If YES , how effective were the nose clips?	(1370)	 □₁ The nose clips sealed the nostrils completely □₂ The nose clips sealed the nostrils partially □₃ The nose clips came off during the procedure □₄Other
	29a. If NO , was the nose occluded?	(1380)	\square_1 Yes \square_0 No
	29ai. If YES , how was the nose occluded?	(1390)	 □₁ Parent/guardian occluded the nose □₂ Technician occluded the nose □₃ Participant occluded the nose □₄ Other
If a	gray box is selected, please explain in the comment section	on belo	w.
COI	MMENTS: (6000)		

METHACHOLINE CHALLENGE TESTING

Supervisor	ID:		

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

(Technician Completed)

Complete this form only if the participant is eligible according to the Methacholine Challenge Testing Checklist (METHACHK) form.

O!:	!- !!	- Only (Table) in Orangle (and						
	Clinic Use Only (Technician Completed) Use the FEV₁ value from the appropriate spirometry testing form as the baseline reference.							
	A. B	aseline (pre) FEV1 prior to methacholine challenge	·	L				
	B. M	ethacholine Reversal Reference Value (Question A x 0	.90 = _	L)				
1.	Pos	t Diluent FEV₁	(1000)	L				
2.	Did →	the participant drop ≥ 20% at the diluent stage? If YES , proceed to Q5. Record 'Yes' for Q5 and 0 for Q5a.	(1010)	□₁ Yes □₀ No				
3.	Last	concentration of methacholine administered	(1020)	mg/ml				
4.	FEV	after last concentration of methacholine administered	(1030)	_·L				
5.	Did →	the participant achieve a PC ₂₀ ? If NO , proceed to Q6.	(1040)	\square_1 Yes \square_0 No				
	5a.	PC ₂₀	(1050)	mg/ml				
6.	Time cloc	e methacholine challenge ended <i>(based on 24-hour k)</i>	(1060)					
7.	Part	icipant's FEV₁ after standard reversal from methacholine c	halleng	е				
		articipant is continuing with sputum induction, standar articipant is not continuing with sputum induction, star						
	7a.	FEV ₁	(1070)	L				
	7b.	Time of FEV ₁ in Q7a (based on 24-hour clock)	(1080)					
	7c.	Was the FEV ₁ from Q7a \geq the methacholine reversal reference value (B) in the gray box above?	(1090)	□₁ Yes □₀ No				
	 → If YES, STOP HERE and continue with remaining visit procedures. → If NO, proceed to the Additional Treatment for Methacholine Challenge Testing 							

(METHA_ADD_TRT) form.

COMMENTS: (6000)

PEDIATRIC METHACHOLINE CHALLENGE TESTING CHECKLIST

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

(Technician Completed)

Complete this form only if the participant is eligible according to the Pulmonary Procedure Checklist form and successfully completed baseline spirometry session(s).

Supervisor ID: _

Evo	lusions	and	Canfa	undoro
-YC	เมรเกทร	ana	เวกทรดเ	unaers

LXC	usions and comounders			
1.	Has the participant had any severe acute illness in the past 4 weeks?	(1000)	☐₁ Yes	□ ₀ No
	1a. If YES, has the participant received permission from the supervising physician to proceed with the methacholine challenge testing?	(1010)	☐₁ Yes	□₀ No
	Physician's Signature:	(1020)		
2.	During the past 4 weeks, has the participant had any respiratory infections, colds, or bronchitis (see the Methacholine MOP)?	(1030)	□₁ Yes	□₀ No
	2a. If YES , during the past 2 weeks, has the participant had any respiratory infections, colds, or bronchitis (see the Methacholine MOP)?	(1040)	□₁ Yes	□₀ No
3.	Has the participant used 4 or more days of systemic corticosteroid (e.g., prednisolone, prednisone, Solumedrol, Decadron) for the treatment of an asthma exacerbation in the past 4 weeks?	(1050)	□ ₁ Yes	□ ₀ No
4.	Does the participant have a baseline (pre-diluent) FEV ₁ less than 70% of predicted?	(1060)	■₁ Yes	□₀ No
5.	Pregnancy test results (Check N/A if the participant is male, or is female and has not started menses.)	(1070)	Positive Negative	
6.	If participant's age is ≥ 12 years: Is the participant's systolic blood pressure > 200 mm Hg or diastolic blood pressure > 100 mm Hg?	(1080)	□₁ Yes	□₀ No
7.	If participant's age is < 12 years: Is the participant's systolic blood pressure > 180 mm Hg or diastolic blood pressure > 90 mm Hg?	(1090)	□ ₁ Yes	□₀ No
8.	Is there any other reason the participant should not proceed with the methacholine challenge testing? If YES , explain:	(1100) (1100D)	☐₁ Yes	□₀ No

METHACHOLINE CHALLENGE TESTING CHECKLIST

Part. ID:	
Visit:	

9.	Is the participant eligible to proceed with the diluent (solution #0) pulmonary function testing for the methacholine challenge?	(1110)	☐ ₁ Yes	□ ₀ No
	If any of the shaded boxes are completed, the participant is NOT eligible for the methacholine challenge testing.			
	→ If YES, proceed to the Methacholine Challenge Testing	ng (ME1	THA) form.	
CON	MMENTS: (6000)			

ADDITIONAL TREATMENT POST METHACHOLINE CHALLENGE TESTING

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

(Technician Completed)

Complete this form only if the participant did not reverse to 90% of baseline (pre) FEV_1 after the first post-challenge treatment of albuterol.

Supervisor ID:

1.	Was →	an additional treatment used in the first hour? If <i>NO</i> , skip to Q3.	(1000)	□₁ Yes	□ ₀ No	
	1a. →	Additional albuterol by MDI If <i>NO</i> , skip to Q1b.	(1010)	☐ ₁ Yes	□ ₀ No	
		Number of additional puffs of albuterol administered	(1020)	□ ₁ 2	□ ₂ 4	$\square_3 > 2$
	1b.	Nebulized Beta-agonist	(1030)	☐ ₁ Yes	\square_0 No	
	1c.	Subcutaneous epinephrine	(1040)	□₁ Yes	\square_0 No	
	1d.	Implementation of clinic emergency protocol or algorithm	(1050)	☐ ₁ Yes	□ ₀ No	
	1e.	Other	(1060)	☐₁ Yes	\square_0 No	
		If YES , specify:	(1060D)			
2.	Parti hour	icipant's FEV ₁ after additional treatment within first				
	2a.	FEV ₁	(1070)	L		
	2b.	Time of FEV ₁ in Q2a (based on 24-hour clock)	(1090)			
	2c.	Was the FEV₁ from Q2a ≥ the methacholine reversal reference value (B) in the gray box on the Methacholine Challenge Testing (METHA) form? → If YES, STOP HERE and continue with remaining visit procedures.	(1100)	□ ₁ Yes	□ ₀ No	
		→ If NO , proceed to Q3.				
3.	Was →	additional treatment used after one hour? If <i>NO</i> , skip to Q4.	(1110)	☐ ₁ Yes	□ ₀ No	
	3a.	Additional albuterol by MDI → If NO, skip to Q3b.	(1120)	□ ₁ Yes	\square_0 No	

ADDITIONAL TREATMENT POST METHACHOLINE

Part. ID:	 	
Visit:		

		Number of additional puffs of albute	rol administered	(1130)	\square_1 2	\square_2 4	$\square_3 > 4$
	3b.	Nebulized Beta-agonist		(1140)	□₁ Yes	\square_0 No	
	3c.	Subcutaneous epinephrine		(1150)	□₁ Yes	\square_0 No	
	3d.	Implementation of clinic emergency algorithm	protocol or	(1160)	□ ₁ Yes	□ ₀ No	
	3e.	Treatment in the emergency room		(1170)	□₁ Yes	\square_0 No	
	3f.	Overnight hospitalization → If <i>YES</i> , please complete the Se Event (SERIOUS) form.	erious Adverse	(1180)	□ ₁ Yes	□ ₀ No	
	3g.	Other		(1190)	□₁ Yes	\square_0 No	
		If YES , specify:		(1190D)			_
4.	Part	ticipant's final FEV₁ after methacholin	e challenge				
	4a.	FEV ₁		(1200)	L	-	
	4b.	Time of FEV ₁ in Q4a (based on 24-	hour clock)	(1220)		-	
	4c.	Was the FEV₁ from Q4a ≥ the methoreference value (B) in the gray box of Methacholine Challenge Testing (M → If <i>NO</i> , complete the source door box below.	on the ETHA) form?	(1230)	□ ₁ Yes	□ ₀ No	
			Physician Source D	Docume	ntation		
			Physician's Signatu	ure:			_ (1240)
			Date:/DD	/ 20 <u> </u>	Y		(1250)
			Time:	(based	on a 24-hour	clock)	(1260)
COI	MMEI	NTS: (6000)					
							

POST-ALBUTEROL (4 puffs) SPIROMETRY TESTING

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

Supervisor ID: __ _ _ _

(Technician Completed)

Complete this form only if the participant is eligible according to the appropriate Pulmonary Procedure Checklist form and successfully completed baseline spirometry session(s).

Pro	cedure Checklist form and successfully completed baseling	e spiroi	metry session(s).					
→	▶ Administer 4 puffs of albuterol and wait 10 to 15 minutes, then perform spirometry.							
1.	Time albuterol administered (based on 24-hour clock)	(1000)						
2.	Time post-albuterol spirometry started (based on 24-hour clock)	(1010)						
The	reported FEV ₁ , FVC and FEF Max are the best measuremen	nts of a	ll acceptable maneuvers.					
3.	Highest FVC	(1020)	L					
4.	Highest FEV ₁	(1030)	L					
5.	Highest FEV ₁ (% predicted)	(1040)	% predicted					
6.	FEF Max	(1050)	L/S					
The	reported FEF ₂₅₋₇₅ corresponds to the maneuver where FEV	+ FVC	is maximized.					
7.	FEF ₂₅₋₇₅	(1060)	L/S					
8.	In your judgment, was the participant's spirometry technique acceptable?	(1070)	\square_1 Yes \square_0 No					
COI	MMENTS: (6000)							

URINE PREGNANCY TEST

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Coordinator ID:

(Coordinator Completed)

Complete this form for female participants ages 6 and older. All female participants ages 6 and older or her parent/quardian must review the completed form and provide source documentation below.

0, 1	ici pe	ineningual diali iniust review the completed form an	ia provide .	source doci	anientation b	CIOW.	
1.	Is th	e participant unable to bear children due to any of the	easons?				
	1a.	Pre-menarche → If YES, stop here and have the parent/guardian complete the source documentation box below.		□ ₁ Yes	□ ₀ No		
	1b.	Post-menopausal (at least one year since last menses)	(1010)	■₁ Yes	\square_0 No		
	1c.	Hysterectomy	(1020)	■₁ Yes	\square_0 No		
	1d.	Tubal ligation	(1030)	☐₁ Yes	\square_0 No		
		→ If any of the shaded boxes are filled in, a pregnancy test is not required. Proceed to the source documentation box below.					
2.	Pre(→	If pregnancy test results are positive, the participant must be terminated from study participation. Complete the appropriate Termination of Study Participation form and follow study termination procedures.	(1040)	□₁ Positiv □₀ Negat			
			Participant/Guardian Source Documentation				
			Participant/Guardian Initials: (
			Date: MM	//20 DD Y		(1060)	
СО	MME	NTS: (6000)					

SPIROMETRY TESTING

Supervisor ID: __ _ _ _

Part. ID:
Part. Initials:
Visit:
Visit Date: / / 20
Technician ID:

(Technician Completed) Complete this form only if the participant is eligible according to the appropriate Pulmonary Procedure Checklist form. Time spirometry started (based on 24-hour clock) (1010)The reported FEV₁, FVC and FEF Max are the best measurements of all acceptable maneuvers. 2. Highest FVC (1020) ___ . __ L (1030) ___ . ___ L 3. Highest FEV₁ (1040) ___ __ % predicted Highest FEV₁ (% predicted) 4. 5. **FEF Max** (1050) ___ . __ L/S The reported FEF_{25-75} corresponds to the maneuver where $FEV_1 + FVC$ is maximized. 6. FEF₂₅₋₇₅ (1060) ___ . __ L/S In your judgment, was the participant's spirometry 7. (1070) \square_1 Yes \square_0 No technique acceptable?

VIIVIEN 1 5: (6000)			